[
  {
    "jumpto": "ENAS5268_2.3.2.0",
    "name": "(5-HT)3 receptor antagonists, doses [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5407_4.5.0.0",
    "name": "(C)RT regimen, selection [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "(FOLFIRINOX), gemcitabine [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "1st-line treat., good/intermed. Px [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "3D conformal RT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5068_5.5.0.0",
    "name": "5-fluorouracil (5-FU)/folinic acid (FA) [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5062_4.1.0.0",
    "name": "5-fluorouracil (5-FU)[Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "5-fluorouracil (5-FU) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "5-FU, in advanced penile CA [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "5-FU [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5285_5.2.1.3",
    "name": "5-year disease-specific survival [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5282_3.1.0.0",
    "name": "18F-FDG-PET (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5271_4.2.1.0",
    "name": "AAIPI in patients ≤60 years, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Abdominal pain (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Abiraterone, palliative care [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Abiraterone, side effects [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Abiraterone, treatment of CRPC [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Abiraterone [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5304_8.6.4.0",
    "name": "Ablative treatment with or without surgery, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_2.2.3.0",
    "name": "AC-treated female patients, breast cancer [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.2.3",
    "name": "AC-treated female pts. with breast cancer, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5410_3.1.1.0",
    "name": "Acantholytic dysker­ato­sis [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Acquired cystic disease-associated RCCs",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5268_4.0.0.0",
    "name": "Acute CINV in children, prevention [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.3.0",
    "name": "Acute emesis [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Acute myeloid leukaemia [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5062_4.4.1.0",
    "name": "Acute pelvic toxicity [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5265_5.1.1.0",
    "name": "Acute treatment, LMWH and UFH [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.1.1.0",
    "name": "Acute treatment, solid tumours [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.1.2.0",
    "name": "Acute treatment, thrombolytic therapy [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.4.1.1",
    "name": "Acute treatment in solid tumours, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.4.1.1",
    "name": "Acute treatment with LMWH and UFH, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.4.1.2",
    "name": "Acute treatment with thrombolytic therapy, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5269_5.9.6.0",
    "name": "Acyclovir [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5282_2.0.0.0",
    "name": "Adenocarcinomas (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5282_4.1.6.0",
    "name": "Adenocarcinomas, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5283_4.3.3.2",
    "name": "Adjuvant 5-FU/leucovorin therapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5092_4.2.2.0",
    "name": "Adjuvant ADT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5094_4.3.0.0",
    "name": "Adjuvant chemotherapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5304_5.7.0.0",
    "name": "Adjuvant chemotherapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "Adjuvant chemotherapy [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5283_4.3.3.1",
    "name": "Adjuvant treatment (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.3",
    "name": "Adjuvant treatment, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5284_7.3.1.6",
    "name": "Adjuvant treatment, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5068_8.3.4.0",
    "name": "Adjuvant treatment in pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5284_4.3.6.0",
    "name": "Adjuvant treatment [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Adjuvant treatment [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "ADT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5270_9.3.3.0",
    "name": "Advanced-stage cHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5064_7.3.3.0",
    "name": "Advanced-stage HCC treatment, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5268_5.1.0.0",
    "name": "Advanced cancer, antiemetics [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5285_5.2.2.1",
    "name": "Advanced disease, overview [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.3.0.0",
    "name": "Advanced disease, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5064_4.4.0.0",
    "name": "Advanced HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_6.0.0.0",
    "name": "Advanced HCC, follow-up",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Advanced pancreatic cancer, palliative care",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5304_5.14.4.0",
    "name": "Aflibercept [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5284_3.2.1.1",
    "name": "AJCC/UICC staging, cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_3.2.2.0",
    "name": "AJCC/UICC staging, gallbladder cancer [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5269_5.4.0.0",
    "name": "Algo., FN mgmt.",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.2.0.0",
    "name": "Algo., primary G-CSF prophylaxis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.10.2.0",
    "name": "Algo., response assessment [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_4.2.0.0",
    "name": "Algorithm, BTC management [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5285_6.2.2.2",
    "name": "Algorithm, systemic treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5263_14.4.0.0",
    "name": "Alimentary tract mucositis, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_5.0.0.0",
    "name": "Alimentary tract mucositis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5281_4.9.1.0",
    "name": "ALK-rearranged NSCLC patients",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.8.0",
    "name": "ALK-rearranged NSCLC patients, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "ALK gene (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Alkylating agents [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Allogeneic haematopoietic stem cell transplantation [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_4.2.6.7",
    "name": "Allograft rejection, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.7.0",
    "name": "Allograft rejection [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5280_4.6.0.0",
    "name": "AlloSCT",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_7.3.6.0",
    "name": "AlloSCT in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5064_5.0.0.0",
    "name": "Alpha fetoprotein",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5262_6.3.3.3",
    "name": "ALT, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.1.0",
    "name": "Alternative therapy, overview [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.1",
    "name": "Alternative therapy, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5262_4.3.5.0",
    "name": "ALT [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Amifostine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Amikacin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "Amphiregulin [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5262_6.3.3.9",
    "name": "Amphotericin, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.11.0",
    "name": "Amphotericin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5063_2.2.1.0",
    "name": "Amsterdam criteria",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Anal cancer, advanced disease",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.3.0.0",
    "name": "Anal cancer, anatomic stage",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.5.0.0",
    "name": "Anal cancer, brachytherapy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.4.1.0",
    "name": "Anal cancer, chemoradiotherapy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_2.1.0.0",
    "name": "Anal cancer, diagnosis",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Anal cancer, diagnostic work-up",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_7.0.0.0",
    "name": "Anal cancer, follow-up",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.1.0.0",
    "name": "Anal cancer, initial mgmt.",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Anal cancer, metastatic disease",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.12.0.0",
    "name": "Anal cancer, palliative care",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.7.0.0",
    "name": "Anal cancer, post-operative chemoradiotherapy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.3.0.0",
    "name": "Anal cancer, prognostic groups",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_5.0.0.0",
    "name": "Anal cancer, quality of life",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.4.2.0",
    "name": "Anal cancer, radiotherapy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_6.0.0.0",
    "name": "Anal cancer, response evaluation",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Anal cancer, risk assessment",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.4.0.0",
    "name": "Anal cancer, risk assessment factors",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.9.0.0",
    "name": "Anal cancer, salvage surgical treatment",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Anal cancer, staging",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.3.0.0",
    "name": "Anal cancer, surgical treatment",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_7.0.0.0",
    "name": "Anal cancer, surveillance",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.2.0.0",
    "name": "Anal cancer, TNM staging",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.6.0.0",
    "name": "Anal cancer, treatment of the elderly",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_8.2.0.0",
    "name": "Anal cancer staging, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Analgesics [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5409_3.0.0.0",
    "name": "Anaphylaxis, clinical criteria for diagnosis [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_3.0.0.0",
    "name": "Anaphylaxis, diagnosis criteria [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5281_3.3.0.0",
    "name": "Anatomic stage (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5061_4.3.0.0",
    "name": "Anatomic stage, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5283_3.3.0.0",
    "name": "Anatomic stage/ prognostic groups (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Angiography, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Angiography, pancreatic arterial",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5273_4.2.0.0",
    "name": "Ann Arbor classification, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5271_3.2.0.0",
    "name": "Ann Arbor staging classification, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_3.4.0.0",
    "name": "Ann Arbor staging classification, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5266_3.2.1.0",
    "name": "Anthracyclines and cytotoxics, overview [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.2.2.0",
    "name": "Anthracyclines and cytotoxics, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Anthracyclines [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5409_11.1.2.0",
    "name": "Anthracyclines [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Anti-angiogenic therapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "Anti-EGFR monoclonal antibody therapies [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5086_5.3.0.0",
    "name": "Anti-folate doublet, unresectable mesothelioma",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5268_5.2.0.0",
    "name": "Anti-secretory drugs [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5304_5.14.4.0",
    "name": "Antiangiogenic [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5262_6.3.3.3",
    "name": "Antibiotic lock therapy, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.5.0",
    "name": "Antibiotic lock therapy [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Antibiotic treatment, CVC-related infections [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Anticancer agents, classification [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5266_8.0.0.0",
    "name": "Anticancer treatment, Tx of LVD [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5268_5.2.0.0",
    "name": "Anticholinergics [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.8.0.0",
    "name": "Anticipatory nausea and vomiting, prev.",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5265_6.0.0.0",
    "name": "Anticoagulation, contraindications [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_7.0.0.0",
    "name": "Anticoagulation and prognosis [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.5.0.0",
    "name": "Anticoagulation contraindications, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Antidotes, after extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5268_2.3.1.0",
    "name": "Antiemetics, dose [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.1.0",
    "name": "Antiemetics, route of administration [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.1.0",
    "name": "Antiemetics, safety [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.1.0",
    "name": "Antiemetics, schedule [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_5.1.0.0",
    "name": "Antiemetics in advanced cancer, overview [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.4.1.0",
    "name": "Antiemetics in advanced cancer, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.2.3.0",
    "name": "Antiemetic treatment options, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_3.4.0.0",
    "name": "Antiemetic treatment options [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Antimetabolites [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "APC-associated FAP",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "APC-associated FAP, definition",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "APC-associated FAP, prevalence",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_6.3.1.0",
    "name": "APC-associated FAP, summary",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.2.2.0",
    "name": "APC germline analysis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Aprepitant [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Arrhythmias [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5410_3.6.3.2",
    "name": "Arthralgia management, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "ASA [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Asbestos exposure [MPM]",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Ascites [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5063_2.4.0.0",
    "name": "Aspirin, Lynch syndrome",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5269_6.4.7.0",
    "name": "Assess. of response, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5407_4.7.2.4",
    "name": "Assessment of distant metastases [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.7.2.3",
    "name": "Assessment of patients planned for surgery [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5269_5.10.1.0",
    "name": "Assessment of response [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5407_4.7.2.1",
    "name": "Assessment of the primary tumour response [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5266_3.4.2.0",
    "name": "Asymptomatic LVD [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5063_4.2.1.0",
    "name": "Attenuated FAP, diagnosis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Atypical mesothelial proliferation, immunohistochemistry (IHC)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5062_4.4.2.0",
    "name": "Australasian planning guidelines",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5098_3.0.0.0",
    "name": "Autoimmune disorders associated with thymoma [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5285_6.2.2.5",
    "name": "Axitinib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Barcelona Clinic Liver Cancer (BCLC) staging",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5063_4.3.0.0",
    "name": "Barium contrast series [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5263_10.2.2.0",
    "name": "Basic oral care protocol, example [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5094_2.0.0.0",
    "name": "BC, diagnosis",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_8.0.0.0",
    "name": "BC, follow-up",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_8.0.0.0",
    "name": "BC, long term implications",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.1.0.0",
    "name": "BC, management of local/ locoregional disease",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.4.0.0",
    "name": "BC, Organ preservation therapy",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_5.2.0.0",
    "name": "BC, second-line therapy",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "BC, staging and risk assessment",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_3.2.0.0",
    "name": "BC, TNM staging",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_2.0.0.0",
    "name": "BC, WHO classification",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_9.1.0.0",
    "name": "BC diagnosis, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_5.2.0.0",
    "name": "BC relapse, treatment",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_9.2.0.0",
    "name": "BC staging and risk assessment, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5268_2.8.0.0",
    "name": "Benzodiazepines [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Benzydamine mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "BEP [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5064_4.4.0.0",
    "name": "Best supportive care (BSC)[HCC]",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5304_5.14.10.3",
    "name": "Best supportive care (BSC) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5282_4.2.0.0",
    "name": "Best supportive care (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5086_5.2.0.0",
    "name": "Best supportive care, MPM",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5063_2.2.2.0",
    "name": "Bethesda guidelines, colorectal tumors",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_5.14.4.0",
    "name": "Bevacizumab [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Bevacizumab [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "Bevacizumab [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5063_5.1.0.0",
    "name": "Biallelic mutations",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Biliary obstruction [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Biliary stent",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Bilio-evteric anastomosis",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5279_3.2.0.0",
    "name": "BINET system [CLL]",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5285_4.0.0.0",
    "name": "Biology [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5282_7.1.0.0",
    "name": "Biopsies, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Biopsy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5284_3.1.0.0",
    "name": "Bismuth-Corlette classification, peri-hilar cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Bisphosphonates, role [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.4.2.3",
    "name": "Bisphosphonates, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Bladder ultrasonography [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "Bleomycin, non-seminoma [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Bleomycin, seminoma [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.1.0.0",
    "name": "Bleomycin/etoposide/cisplatin (BEP) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "Blood tests in TS/T-NS",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5410_3.1.3.2",
    "name": "Body surface area schematic [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5281_4.14.2.0",
    "name": "Bone metastases (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.13.2",
    "name": "Bone metastases, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "Bone scan [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "Bowenoid papulosis [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "Bowen’s disease [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5062_8.3.4.0",
    "name": "Brachytherapy in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5096_4.2.0.0",
    "name": "Brachytherapy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5304_8.5.2.0",
    "name": "BRAF, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "BRAF mutation status [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.2.0",
    "name": "BRAF mutations [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Brain and bone metastases (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.13.1",
    "name": "Brain and bone metastases, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Brain metastases (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.13.1",
    "name": "Brain metastases, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "BRCA1 [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "BRCA2 [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5268_6.1.7.0",
    "name": "Breakthrough ChT-induced emesis, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.7.0",
    "name": "Breakthrough refractory emesis, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.2.3.0",
    "name": "Breast cancer, AC-treated female patients [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_14.8.3.0",
    "name": "Bristol stool chart, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_9.3.0.0",
    "name": "Bristol stool chart [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5284_4.2.0.0",
    "name": "BTC management algorithm [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5068_3.0.0.0",
    "name": "CA 19-9 [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Cabazitaxel, treatment of CRPC [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Cabazitaxel [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5285_6.2.2.6",
    "name": "Cabozantinib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Calretinin",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5283_5.0.0.0",
    "name": "Cancer genome atlas (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5262_6.3.3.9",
    "name": "Candida, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.10.0",
    "name": "Candidaemia [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5262_4.3.11.0",
    "name": "Candida [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_6.4.6.10",
    "name": "Candidiasis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.10.0",
    "name": "Candidiasis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5267_5.0.0.0",
    "name": "Cannulation [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5283_4.3.2.0",
    "name": "Capecitabine, perioperative chemotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5263_5.0.0.0",
    "name": "Capecitabine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Capecitabine [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5304_5.7.0.0",
    "name": "CAPOX [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Capsule endoscopy",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Carbo-Px [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "CarboGem [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5068_3.0.0.0",
    "name": "Carbohydrate antigen (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "Carboplatin, MPM therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5268_6.1.4.2",
    "name": "Carboplatin, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Carboplatin/gemcitabine [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Carboplatin [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5268_2.4.2.0",
    "name": "Carboplatin [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Carboplatin [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Carboplatin [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Carboplatin [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Carcinoembryonic antigen (CEA)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Carcinoembryonic antigen (CEA)[Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Cardiac function after chest RT, monitoring [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.3.0.0",
    "name": "Cardiac ischaemia, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_4.0.0.0",
    "name": "Cardiac ischaemia [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5410_4.2.6.2",
    "name": "Cardiac toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5266_9.1.0.0",
    "name": "Cardiac toxicity induced by RT, overview [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.8.1.0",
    "name": "Cardiac toxicity induced by RT, summary [ CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5410_3.6.2.0",
    "name": "Cardiac toxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Cardiomyopathy [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_3.2.2.0",
    "name": "Cardiotoxicity, mgmt.",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5262_5.3.0.0",
    "name": "Catheter-induced thrombosis, diagnosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.1.0.0",
    "name": "Catheter-induced thrombosis, overview [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.6.0.0",
    "name": "Catheter-induced thrombosis, prevention [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.2.0.0",
    "name": "Catheter-induced thrombosis, risk factors [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.4.0.0",
    "name": "Catheter-induced thrombosis, treatment [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.2.0",
    "name": "Catheter-related infection [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5262_5.5.2.0",
    "name": "Catheter-related thrombosis, prevention [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Catheter-related thrombosis, treatment [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.6.0",
    "name": "Ceftazidime [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.7",
    "name": "Cellulitis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.7.0",
    "name": "Cellulitis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.2",
    "name": "Central IV catheters, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.2.0",
    "name": "Central IV catheters [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_3.6.1.4",
    "name": "Central neurological toxicity mgmt., interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5267_9.1.0.0",
    "name": "Central venous access device extravasation, overview",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.8.0.0",
    "name": "Central venous access device extravasation, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Central venous access device [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Cervical intra-epithelial neoplasia (CIN)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5063_4.3.0.0",
    "name": "Cervical ultrasonography [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_5.14.5.0",
    "name": "Cetuximab + irinotecan [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5409_11.2.2.0",
    "name": "Cetuximab [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "Cetuximab [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5283_4.2.0.0",
    "name": "CF, cisplatin/5-fluorouracil (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5267_6.3.0.0",
    "name": "Chemical phlebitis [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_6.2.0.0",
    "name": "Chemical phlebitis [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "Chemoembolisation [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Chemoprevention, Fam. Colorectal cancer",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5269_6.2.0.0",
    "name": "Chemoprophylaxis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_3.0.0.0",
    "name": "Chemoprophylaxis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5283_4.3.3.2",
    "name": "Chemoradiotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5062_4.4.1.0",
    "name": "Chemoradiotherapy, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5068_5.6.2.0",
    "name": "Chemoradiotherapy, capectabine [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.6.2.0",
    "name": "Chemoradiotherapy, locally advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5407_4.8.1.0",
    "name": "Chemoradiotherapy, postoperative indications [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_8.3.1.3",
    "name": "Chemoradiotherapy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5062_8.3.3.0",
    "name": "Chemoradiotherapy in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Chemoradiotherapy [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5283_4.3.3.3",
    "name": "Chemotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Chemotherapy, definitive [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5263_10.2.1.0",
    "name": "Chemotherapy, mucositis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "Chemotherapy, PenCa",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_5.6.0.0",
    "name": "Chemotherapy, post-op [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5407_4.8.2.0",
    "name": "Chemotherapy, postoperative [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.7.1.0",
    "name": "Chemotherapy, preoperative [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_8.3.1.3",
    "name": "Chemotherapy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5265_2.2.0.0",
    "name": "Chemotherapy-associated VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5268_4.0.0.0",
    "name": "Chemotherapy-induced nausea and vomiting in children",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Chemotherapy-induced nausea and vomiting [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5098_5.12.0.0",
    "name": "Chemotherapy for advanced TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5096_7.3.3.0",
    "name": "Chemotherapy in PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, BEP (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, EP (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, TI-CE (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, TIP (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, VeIP (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "Chemotherapy regimens, VIP/PEI (TS)",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5304_8.5.4.0",
    "name": "Chemotherapy sensitivity, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Chemotherapy sensitivity [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.3.1.0",
    "name": "Chemotherapy with platinum-doublets (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5097_4.1.0.0",
    "name": "Chemotherapy [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Child-Pugh (CP) scoring",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Chlorhexidine mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5269_6.4.5.2",
    "name": "Choice of IV antibacterial, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.7.2.0",
    "name": "Choice of IV antibacterial [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_3.2.1.1",
    "name": "Cholangiocarcinoma, AJCC/UICC staging [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_3.2.1.3",
    "name": "Cholangiocarcinoma, distal [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_3.2.1.1",
    "name": "Cholangiocarcinoma, intra-hepatic [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_3.2.1.2",
    "name": "Cholangiocarcinoma, peri-hilar [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5410_3.6.5.0",
    "name": "Choroidal neovascularisation, treatment",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5406_5.1.3.0",
    "name": "Chronic obstructive pulmonary disease [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5268_2.7.0.0",
    "name": "ChT-induced emesis [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5267_6.3.0.0",
    "name": "ChT drugs, causing local reactions [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5268_2.6.0.0",
    "name": "ChT with low & minimal emetogenic potential, prev. [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "CINV, prevention",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Ciprofloxacin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Circulating tumour cell (CTC) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Cisplatin, definitive chemotherapy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5071_4.2.0.0",
    "name": "Cisplatin, localised SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "Cisplatin, MPM therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5281_4.3.1.0",
    "name": "Cisplatin-based chemotherapy (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5096_4.3.0.0",
    "name": "Cisplatin-based chemotherapy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5094_4.3.0.0",
    "name": "Cisplatin-based neoadjuvant chemotherapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "Cisplatin-based [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Cisplatin-containing combination chemotherapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5268_6.1.2.2",
    "name": "Cisplatin-treated patients, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Cisplatin-treated patients [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5282_4.1.6.0",
    "name": "Cisplatin/5-FU combined with 41.4–50.4 Gy RT (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5281_4.3.2.0",
    "name": "Cisplatin and gemcitabine, treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Cisplatin [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Cisplatin [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "Cisplatin [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Cisplatin [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5280_4.2.2.0",
    "name": "Cladribine",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5063_4.2.1.0",
    "name": "Classical FAP, diagnosis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5280_4.2.5.0",
    "name": "Classical HCL: Tx of newly diagnosed",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_4.4.2.0",
    "name": "Classical HCL: Tx of relapsed & refractory, interactive tool",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Classification, anticancer agents [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Classification [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5094_6.0.0.0",
    "name": "Clinical mgmt.overview, interactive tool [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "Clinical myasthenia gravis [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Clinical trials [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "Clinical trials [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5269_5.9.9.0",
    "name": "Clostridium difficile [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.2.0",
    "name": "CNS bacteraemia [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5271_7.3.2.0",
    "name": "CNS prophylaxis in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Coeliac axis (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Coeliac plexus block (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5061_5.2.0.0",
    "name": "Colonic resection [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5062_2.1.0.0",
    "name": "Colonoscopy [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Colonoscopy [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5304_5.2.2.0",
    "name": "Colorectal liver metastases (CLM) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.5.0.0",
    "name": "Colorectal liver metastases [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Combination chemotherapy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5269_5.6.1.0",
    "name": "Combination therapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5273_5.4.0.0",
    "name": "Combined chemoimmunotherapy in FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5408_3.1.0.0",
    "name": "Combined MIPI [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Common hepatic artery (CHA)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Common initial symptoms, extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.5.1.0",
    "name": "Common initial symptoms, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Complete endoscopic polypectomy",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5281_4.5.0.0",
    "name": "Comprehensive geriatric assessment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Computed tomography (CT) [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Computed tomography (CT) [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Computed tomography [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5268_6.2.4.0",
    "name": "Concurrent chemoradiotherapy, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_3.5.0.0",
    "name": "Concurrent chemoradiotherapy [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5086_5.4.3.0",
    "name": "Conformal radiotherapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Congenital hypertrophy of retinal pigmented epithelium",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5273_5.5.0.0",
    "name": "Consolidation/ maintenance, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5273_8.3.2.0",
    "name": "Consolidation/maintenance of FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5266_3.4.3.0",
    "name": "Continuation of trastuzumab, LVEF [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5265_6.0.0.0",
    "name": "Contraindications, anticoagulation [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.5.0.0",
    "name": "Contraindications to anticoagulation, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "Contrast-enhanced CT (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Contrast-enhanced ultrasound (CEUS)",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5283_4.3.3.2",
    "name": "Conventionally fractionated radiotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5304_8.6.2.5",
    "name": "Conversion strategic treatment goal, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.3.0",
    "name": "Conversion treatment, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.9.0.0",
    "name": "Conversion treatment [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_2.3.3.0",
    "name": "Corticosteroids, doses [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Corticosteroids [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5268_3.3.0.0",
    "name": "Craniospinal irradiation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_4.1.0.0",
    "name": "CRBSI [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5063_4.3.0.0",
    "name": "CRC screening [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5281_4.9.1.0",
    "name": "Crizotinib, treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5269_5.9.2.0",
    "name": "CRI [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Crohn's disease",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5407_9.3.3.0",
    "name": "CRT regimen, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "Cryoablation [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "CT, PC follow-up [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "CT abdomen [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5061_3.0.0.0",
    "name": "CT colonography",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "CT thorax [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "CT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "CT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "CT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5266_3.2.1.0",
    "name": "Cumulative dose-related cardiotoxicity, overview [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.2.2.0",
    "name": "Cumulative dose-related cardiotoxicity, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Curative treatment (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5276_4.8.0.0",
    "name": "Cutaneous B-cell lymphoma (CBCL)",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.9.0",
    "name": "Cutaneous B-cell lymphoma (CBCL), summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5267_9.2.0.0",
    "name": "CVAD extravasation, steps",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5262_4.1.0.0",
    "name": "CVC-related infection, overview",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "CVC-related infections, antibiotic treatment [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.4.0.0",
    "name": "CVC-related infections, prevention",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.2.0.0",
    "name": "CVC infections, diagnosis",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.2.0",
    "name": "CVC infections, management",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.1.0",
    "name": "CVC infections, treatment",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.4.0",
    "name": "CVC removal , indications",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5266_10.1.0.0",
    "name": "CV eval. before anticancer treatment, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "CV eval. before anticancer treatment [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_7.0.0.0",
    "name": "CV monitoring, after anticancer Tx [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_7.0.0.0",
    "name": "CV monitoring, during anticancer Tx [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.6.0.0",
    "name": "CV monitoring after anticancer Tx, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.6.0.0",
    "name": "CV monitoring during anticancer Tx, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5283_4.2.0.0",
    "name": "CX, cisplatin/capecitabine (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Cyclophosphamide, second-line treatment [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Cyfra 21.1 [MPM]",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5094_8.0.0.0",
    "name": "Cystoscopy, BC follow-up [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_7.0.0.0",
    "name": "Cystoscopy, management of BC [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Cystoscopy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5409_4.0.0.0",
    "name": "Cytokine release syndrome [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5304_5.14.7.0",
    "name": "Cytoreduction (Shrinkage) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.6.0",
    "name": "Cytoreduction [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Cytoreductive nephrectomy [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_8.6.6.0",
    "name": "Cytoreductive surgery, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.13.0.0",
    "name": "Cytoreductive surgery [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5062_4.1.0.0",
    "name": "Cytotoxic agents [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Cytotoxic doublet [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Cytotoxic triplet [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5269_6.4.7.0",
    "name": "Daily follow-up, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.10.1.0",
    "name": "Daily follow-up [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Dalteparin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.3.7",
    "name": "Daptomycin, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.9.0",
    "name": "Daptomycin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.7.0",
    "name": "Daptomycin [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_7.3.1.4",
    "name": "dCCA, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.4.0",
    "name": "dCCA [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5278_3.3.0.0",
    "name": "Deauville criteria",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Decompensated cirrhosis",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5267_2.0.0.0",
    "name": "Definition, extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.1.0.0",
    "name": "Definition of extravasation, summary",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5098_8.3.8.0",
    "name": "Definitive chemotherapy, summary [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_8.3.7.0",
    "name": "Definitive radiotherapy, summary [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_5.9.0.0",
    "name": "Definitive RT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5268_2.3.3.0",
    "name": "Delayed emesis [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Denosumab [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Denosumab [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_5.9.0.0",
    "name": "Depth of response [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Desmoid tumor",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Dexamethasone, metastases (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Dexamethasone [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Dexamethasone [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Dexrazoxane [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5410_3.2.3.0",
    "name": "Diabetes mellitus [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Diagnosis (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Diagnosis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_2.0.0.0",
    "name": "Diagnosis (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5262_5.3.0.0",
    "name": "Diagnosis, catheter-induced thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5279_2.0.0.0",
    "name": "Diagnosis, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5262_4.2.0.0",
    "name": "Diagnosis, CVC infections",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5271_2.0.0.0",
    "name": "Diagnosis, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_2.1.0.0",
    "name": "Diagnosis, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_3.0.0.0",
    "name": "Diagnosis, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5406_3.0.0.0",
    "name": "Diagnosis, early NSCLC",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Diagnosis, extravasation [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5273_2.0.0.0",
    "name": "Diagnosis, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_2.1.0.0",
    "name": "Diagnosis, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Diagnosis, hepatocellular cancer",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5270_2.0.0.0",
    "name": "Diagnosis, Hodgkin’s lymphoma",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_2.0.0.0",
    "name": "Diagnosis, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5265_3.0.0.0",
    "name": "Diagnosis, occult cancer idiopathic VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5278_2.5.0.0",
    "name": "Diagnosis, PBL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_2.6.0.0",
    "name": "Diagnosis, PBoL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5276_2.0.0.0",
    "name": "Diagnosis, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5278_2.4.0.0",
    "name": "Diagnosis, PCNSL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_2.2.0.0",
    "name": "Diagnosis, PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5277_2.0.0.0",
    "name": "Diagnosis, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5278_2.3.0.0",
    "name": "Diagnosis, PTL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Diagnosis, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5071_2.0.0.0",
    "name": "Diagnosis, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5271_5.2.1.0",
    "name": "Diagnosis, staging and risk assessment (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_7.4.2.1",
    "name": "Diagnosis, staging and risk assessment in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5281_7.1.0.0",
    "name": "Diagnosis, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_7.1.0.0",
    "name": "Diagnosis, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5284_7.1.0.0",
    "name": "Diagnosis, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5267_12.5.1.0",
    "name": "Diagnosis, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_8.1.0.0",
    "name": "Diagnosis, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_14.7.0.0",
    "name": "Diagnosis, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_9.1.0.0",
    "name": "Diagnosis, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5274_2.0.0.0",
    "name": "Diagnosis, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5283_8.1.0.0",
    "name": "Diagnosis and pathology (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5407_9.1.0.0",
    "name": "Diagnosis and pathology of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5262_6.4.3.0",
    "name": "Diagnosis of catheter-induced thrombosis, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5063_4.2.1.0",
    "name": "Diagnosis of classical FAP",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5279_7.1.0.0",
    "name": "Diagnosis of CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5262_6.3.2.0",
    "name": "Diagnosis of CVC infections, summary",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5271_7.1.0.0",
    "name": "Diagnosis of DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.1.1.0",
    "name": "Diagnosis of DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_8.2.0.0",
    "name": "Diagnosis of early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5273_8.1.0.0",
    "name": "Diagnosis of FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.1.0.0",
    "name": "Diagnosis of HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_9.1.0.0",
    "name": "Diagnosis of HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.1.0.0",
    "name": "Diagnosis of MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5408_7.1.0.0",
    "name": "Diagnosis of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Diagnosis of MPM",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5265_8.2.0.0",
    "name": "Diagnosis of occult cancer idiopathic VTE, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5278_7.1.5.0",
    "name": "Diagnosis of PBL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_7.1.6.0",
    "name": "Diagnosis of PBoL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5092_7.1.0.0",
    "name": "Diagnosis of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5276_7.1.0.0",
    "name": "Diagnosis of PCLs, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5278_7.1.4.0",
    "name": "Diagnosis of PCNSL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5096_7.1.0.0",
    "name": "Diagnosis of PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5278_7.1.2.0",
    "name": "Diagnosis of PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5277_7.1.0.0",
    "name": "Diagnosis of PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5278_7.1.3.0",
    "name": "Diagnosis of PTL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5071_6.1.0.0",
    "name": "Diagnosis of SCLC, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_8.1.0.0",
    "name": "Diagnosis of TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_7.1.0.0",
    "name": "Diagnosis of WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5284_2.0.0.0",
    "name": "Diagnosis [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5408_2.0.0.0",
    "name": "Diagnosis [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_2.0.0.0",
    "name": "Diagnosis [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_8.0.0.0",
    "name": "Diagnosis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_2.0.0.0",
    "name": "Diagnosis [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Diagnosis [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5279_3.1.0.0",
    "name": "Diagnostic and staging work-up, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5278_3.2.0.0",
    "name": "Diagnostic work-up, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5273_4.3.0.0",
    "name": "Diagnostic work-up, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_2.2.0.0",
    "name": "Diagnostic work-up, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5407_3.3.0.0",
    "name": "Diagnostic work-up in primary rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5269_6.4.6.9",
    "name": "Diarrhoea, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5263_14.8.4.0",
    "name": "Diarrhoea, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5410_3.4.1.3",
    "name": "Diarrhoea and colitis management, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001767",
    "name": "Diarrhoea and colitis management, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5269_5.9.9.0",
    "name": "Diarrhoea [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5263_9.4.0.0",
    "name": "Diarrhoea [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5283_7.0.0.0",
    "name": "Dietary support for vit. and mineral deficiencies (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.6.0.0",
    "name": "Dietary support for vit. and mineral deficiencies (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5268_2.2.4.0",
    "name": "Differences, NK1 RAs [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5267_6.2.0.0",
    "name": "Differential diagnosis, extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.5.2.0",
    "name": "Differential diagnosis, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5278_2.1.0.0",
    "name": "Diffuse large B-cell lymphoma (DLBCL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Digital rectal examination",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Digital rectal examination, risk assessment",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "Digital rectal examination [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Digital rectal examination [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Dihydropyrimidine dehydrogenase (DPD) testing [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5266_3.4.3.0",
    "name": "Discontinuation of trastuzumab [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5304_8.6.9.0",
    "name": "Discontinuation of treatment, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.7.0",
    "name": "Disease control (control of progression) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_4.0.0.0",
    "name": "Diseases of chromosome 3p [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5284_3.2.1.3",
    "name": "distal, cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_7.3.1.4",
    "name": "Distal cholangiocarcinoma, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.4.0",
    "name": "Distal cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5281_3.2.0.0",
    "name": "Distant metastasis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5271_7.3.1.0",
    "name": "DLBCL treatment stratified according to age, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "DNA-binding compounds [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5063_2.2.1.0",
    "name": "DNA sequencing",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Docetaxel, side effects, [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Docetaxel and nintedanib, Second-line treatment in NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "Docetaxel and nintedanib second-line treatment in NSCC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Docetaxel and ramucirumab, Second-line treatment in NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "Docetaxel and ramucirumab second-line treatment in NSCC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Docetaxel [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5267_12.9.0.0",
    "name": "Documentation, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_10.0.0.0",
    "name": "Documentation [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5268_2.3.2.0",
    "name": "Dolasetron [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.3.1",
    "name": "Dose of antiemetics, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Dose of G-CSF, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Dose of pegfilgrastim, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5268_2.3.2.0",
    "name": "Doses, (5-HT)3 receptor antagonists [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.3.0",
    "name": "Doses, corticosteroids [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.4.0",
    "name": "Doses, NK1 receptor antagonists[N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5086_5.4.3.0",
    "name": "Dosimetric constraints, EPP",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5281_4.5.0.0",
    "name": "Doublet therapy (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Doxepin mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Doxorubicin, second-line treatment [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Doxorubicin [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Doxorubicin [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "DRE, PC follow-up [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "DRE [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Duodenal polyps",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5269_6.4.8.0",
    "name": "Duration of therapy, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.11.0.0",
    "name": "Duration of therapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5265_8.4.3.0",
    "name": "Duration of Tx to prevent VTE recurr., summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.3.0.0",
    "name": "Duration of Tx to prevent VTE recurrence",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5280_2.3.0.0",
    "name": "Dx criteria for HCL and HCL-V",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Dynamic contrast-enhanced MRI",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5061_8.4.5.0",
    "name": "Early coln cancer implications, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5061_8.4.5.0",
    "name": "Early colon cancer follow-up, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5061_8.4.3.0",
    "name": "Early colon cancer treatment, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5406_3.0.0.0",
    "name": "Early NSCLC, diagnosis",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_2.0.0.0",
    "name": "Early NSCLC, screening",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5064_7.3.1.0",
    "name": "Early stage HCC treatment, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5304_5.9.0.0",
    "name": "Early tumour shrinkage [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5277_7.3.2.0",
    "name": "EATL in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5281_4.3.1.0",
    "name": "EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.1",
    "name": "EGFR- and ALK-negative disease, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.2.1",
    "name": "EGFR- and ALK-negative disease, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.7.0",
    "name": "EGFR-mutated, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.8.1.0",
    "name": "EGFR-mutated NSCLC patients",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_4.2.2.0",
    "name": "EGFR antibody therapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "EGFR ligands [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "EGFR mutations (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "EGFR mutation testing (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.8.1.0",
    "name": "EGFR TKIs (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.5.0.0",
    "name": "Elderly patients, management (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5283_8.3.3.0",
    "name": "Elderly patients, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_7.3.4.0",
    "name": "Elderly patients, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_8.6.12.3",
    "name": "Elderly patients, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5283_4.5.0.0",
    "name": "Elderly patients with gastric cancer",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5263_11.3.0.0",
    "name": "Emergent data, systematic enteral nutrition [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.10.3.0",
    "name": "Emergent data of systematic enteral nutrition, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "Emerging biomarkers [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Emerging technologies [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Emetogenicity, levels [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Emetogenic potential [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_6.4.6.6",
    "name": "Encephalitis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.6.0",
    "name": "Encephalitis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Endo-anal ultrasound (EAUS)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5407_3.3.0.0",
    "name": "Endorectal ultrasound [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Endoscopic mucosal resection, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Endoscopic mucosal resection, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Endoscopic polypectomy [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Endoscopic resection, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Endoscopic resection, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Endoscopic resection criteria, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5284_2.0.0.0",
    "name": "Endoscopic retrograde cholangiopancreatography [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5282_4.1.1.0",
    "name": "Endoscopic stenting, treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Endoscopic sub-mucosal dissection, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Endoscopic submucosal dissection, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Endoscopic ultrasound (EUS)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "Endoscopic ultrasound (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5277_7.3.3.0",
    "name": "ENKTCL in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Enoxaparin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.3.7",
    "name": "Enterococcus, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.9.0",
    "name": "Enterococcus [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5277_4.4.0.0",
    "name": "Enteropathy-associated T-cell lymphoma (EATL)",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Enzalutamide, palliative care [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Enzalutamide, side effects [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Enzalutamide, treatment of CRPC [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Enzalutamide [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Epidermal growth factor receptor (EGFR) [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Epidermoid cyst",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "Epiregulin [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Epirubicin [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Epithelioid angiomyolipoma [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "EP [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "Erlotinib, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.6.0.0",
    "name": "Erlotinib switch maintenance (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Erlotinib [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "Erythroplasia of Queyrat [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5268_3.2.0.0",
    "name": "ESMO antiemetic guidelines [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5071_4.2.0.0",
    "name": "Etoposide, localised SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Etoposide/ifosfamide/cisplatin (VIP/PEI) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "European Society of Gastrointestinal Endoscopy",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5285_6.2.2.5",
    "name": "Everolimus [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Examination under anaesthesia (EUA)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5263_10.2.2.0",
    "name": "Example, basic oral care protocol [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Excision repair cross-complementation group 1 (ERCC1) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5062_4.4.2.0",
    "name": "Exophytic tumors",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5304_5.1.0.0",
    "name": "Expert multidisciplinary team (MDT) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.1.0.0",
    "name": "Expert multidisciplinary team (MDT) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5086_5.5.3.0",
    "name": "Extended decortification, surgery in MPM",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.3.0",
    "name": "Extended pleurectomy, surgery in MPM",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5096_4.2.0.0",
    "name": "External beam radiotherapy (EBRT) [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5064_4.5.0.0",
    "name": "External beam radiotherapy, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5277_4.5.0.0",
    "name": "Extranodal natural killer/T-cell lymphoma (ENKTCL)",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5276_4.6.0.0",
    "name": "Extranodal NK/T-cell lymphoma, nasal type",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.7.0",
    "name": "Extranodal NK/T-cell lymphoma, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5086_5.4.2.0",
    "name": "Extrapleural pneumonectomy (EPP)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.4.3.0",
    "name": "Extrapleural pneumonectomy, choice of radiation",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Extravasation, common initial symptoms",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_2.0.0.0",
    "name": "Extravasation, definition",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Extravasation, diagnosis [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Extravasation, Later symptoms",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_5.0.0.0",
    "name": "Extravasation, prevention [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Extravasation, risk factors [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "FA/5-FU/irinotecan/oxaliplatin",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5062_2.1.0.0",
    "name": "Faecal incontinence",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Familial adenoomatous polyposis (FAP)[Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Familial cancer syndrome (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5063_3.1.0.0",
    "name": "Familial colorectal cancer X syndrome",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_3.1.0.0",
    "name": "Familial colorectal cancer X syndrome, definition",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_6.2.0.0",
    "name": "Familial colorectal cancer X syndrome, summary",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_3.2.0.0",
    "name": "Familial colorectal cancer X syndrome, surveillance",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "FDG-PET-CT scanning (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "FDG-PET-CT scanning (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "FDG-PET/CT [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "FDG-PET scan in TS",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "FDG-PET [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "FDG-PET [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5269_2.0.0.0",
    "name": "Febrile neutropaenia",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Fibrinous pleurisy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Fibulin-3 [MPM]",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5273_8.3.1.0",
    "name": "First-line of Rx in FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.3.2.0",
    "name": "First-line of Rx in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5408_4.1.0.0",
    "name": "First-line of Rx stage I-II [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_4.2.0.0",
    "name": "First-line of Rx stage III-IV [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5273_5.1.2.0",
    "name": "First-line of Rx stage III–IV, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5273_5.1.1.0",
    "name": "First-line of Rx stage I–II, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5274_4.2.0.0",
    "name": "First-line of treatment, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5274_7.3.2.0",
    "name": "First-line of treatment in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5408_7.3.1.0",
    "name": "First-line Rx of MCL stage I-II, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_7.3.2.0",
    "name": "First-line Rx of MCL stage III-IV, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5285_6.2.2.4",
    "name": "First-line treat., poor prognosis [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5281_4.3.1.0",
    "name": "First-line treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.2.1",
    "name": "First-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_9.4.2.2",
    "name": "First-line treatment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5281_4.3.3.0",
    "name": "First-line treatment for NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.3.2.0",
    "name": "First-line treatment for SCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5278_4.1.0.0",
    "name": "First-line treatment strategies, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "FISH, diagnosis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "FISH, fluorescence in situ hybridisation (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_2.1.0.0",
    "name": "Fistulae",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.9.0.0",
    "name": "Flap reconstruction",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Flexible sigmoidoscopy [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5063_4.3.0.0",
    "name": "Flexible sigmoidoscopy [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5273_4.4.0.0",
    "name": "FLIPI risk factors",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5269_5.9.10.0",
    "name": "Fluconazole [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5282_4.1.6.0",
    "name": "Fluoropyrimidine, treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5269_5.1.0.0",
    "name": "FN, management",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.1.0.0",
    "name": "FN, summary",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5096_6.3.0.0",
    "name": "FNAC biopsy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5269_5.8.0.0",
    "name": "FN management, key recommendations",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.4.0.0",
    "name": "FN mgmt., algo.",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "FOBT screening",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "FOLFIRINOX (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "FOLFIRINOX, 5-FU/cisplatin",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "FOLFIRINOX, metastatic pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5304_5.7.0.0",
    "name": "FOLFOX [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Follicle-stimulating hormone (FSH) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5283_7.0.0.0",
    "name": "Follow-up & long term implications (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_6.0.0.0",
    "name": "Follow-up (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5271_5.1.0.0",
    "name": "Follow-up, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_6.0.0.0",
    "name": "Follow-up, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_7.0.0.0",
    "name": "Follow-up, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5270_8.0.0.0",
    "name": "Follow-up, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5283_8.6.0.0",
    "name": "Follow-up, long term implications, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_7.6.0.0",
    "name": "Follow-up, long term implications, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5275_6.0.0.0",
    "name": "Follow-up, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5276_6.0.0.0",
    "name": "Follow-up, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5071_5.0.0.0",
    "name": "Follow-up, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5281_7.5.0.0",
    "name": "Follow-up, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5284_7.5.0.0",
    "name": "Follow-up, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5267_12.10.0.0",
    "name": "Follow-up, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5285_9.6.0.0",
    "name": "Follow-up, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "Follow-up, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_6.0.0.0",
    "name": "Follow-up, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5407_9.7.0.0",
    "name": "Follow-up. Long term implications and survivorship, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5273_7.2.0.0",
    "name": "Follow-up after end of therapy, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5279_6.0.0.0",
    "name": "Follow-up and long-term implications, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5273_7.1.0.0",
    "name": "Follow-up and long-term implications, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_6.0.0.0",
    "name": "Follow-up and long-term implications, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5279_7.5.0.0",
    "name": "Follow-up and long-term implications in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5273_8.5.0.0",
    "name": "Follow-up and long-term implications in FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5408_7.5.0.0",
    "name": "Follow-up and long-term implications in MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5094_9.6.0.0",
    "name": "Follow-up and long term implications in BC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5280_7.5.0.0",
    "name": "Follow-up and long term implications in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5092_7.5.0.0",
    "name": "Follow-up and long term implications in PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5062_8.6.0.0",
    "name": "Follow-up in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5271_7.4.1.0",
    "name": "Follow-up in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.5.0.0",
    "name": "Follow-up in DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5064_7.3.5.0",
    "name": "Follow-up in HCC, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5270_9.7.0.0",
    "name": "Follow-up in HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.5.0.0",
    "name": "Follow-up in MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5276_7.4.0.0",
    "name": "Follow-up in PCLs, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5096_7.5.0.0",
    "name": "Follow-up in PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5097_7.4.0.0",
    "name": "Follow-up in TS/T-NS, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5274_7.5.0.0",
    "name": "Follow-up in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5282_6.0.0.0",
    "name": "Follow-up long term implications (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5068_8.5.0.0",
    "name": "Follow-up of pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5284_6.0.0.0",
    "name": "Follow-up [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5267_11.0.0.0",
    "name": "Follow-up [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5408_6.0.0.0",
    "name": "Follow-up [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5263_13.0.0.0",
    "name": "Follow-up [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_8.0.0.0",
    "name": "Follow-up [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5407_8.1.0.0",
    "name": "Follow-up [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_4.3.3.4",
    "name": "Following preoperative chemotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Fondaparinux [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5304_5.2.2.0",
    "name": "FONG score [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Foseprepitant [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "FP monotherapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5279_4.2.2.2",
    "name": "Front-line treatment algo., interactive tool",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Fuhrman’s grade, management of metastatic disease [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "Fusion biopsy [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "G-CSF, dose [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "G-CSF, route of application [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "G-CSF, schedule [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_3.2.2.0",
    "name": "Gallbladder cancer, AJCC/UICC staging [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_7.3.1.5",
    "name": "Gallbladder cancer, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.5.0",
    "name": "Gallbladder cancer [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5269_5.9.5.0",
    "name": "Ganciclovir [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Gardner's syndrome",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5283_4.2.0.0",
    "name": "Gastric CA treatment algo., interactive tool",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5275_4.2.0.0",
    "name": "Gastric MALT lymphoma stage IE-IIE, interactive tool",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5275_4.3.0.0",
    "name": "Gastric MALT lymphoma stage III-IV, interactive tool",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Gastric polyps",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.3.0.0",
    "name": "Gastroduodenal endoscopy [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5263_14.8.3.0",
    "name": "Gastrointestinal mucositis grading, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_9.3.0.0",
    "name": "Gastrointestinal mucositis grading [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Gastrointestinal mucositis guideline [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Gastrointestinal stromal tumours (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5410_4.2.4.1",
    "name": "Gastrointestinal toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5284_7.3.1.5",
    "name": "GBC, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.5.0",
    "name": "GBC [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "GC [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5275_4.6.0.0",
    "name": "Gela grading system",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5409_2.0.0.0",
    "name": "Gell and coombs classification [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Gemcitabine(Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.5.0.0",
    "name": "Gemcitabine, gemicitabine [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.6.2.0",
    "name": "Gemcitabine, locally advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Gemcitabine, metastatic pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Gemcitabine-refractory [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Gemcitabine/cisplatin (GC) [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "Gemcitabine [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5267_12.6.2.0",
    "name": "General measures, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_7.2.0.0",
    "name": "General measures [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_4.2.3.0",
    "name": "Genetic counselling [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Gentamicin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "Germ cell tumour (GCT) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5268_2.5.0.0",
    "name": "Germ cell tumours [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5063_2.2.1.0",
    "name": "Germline genetic testing",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5263_14.6.0.0",
    "name": "GI mucositis in targeted therapy, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_7.0.0.0",
    "name": "GI mucositis in targeted therapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5410_3.4.1.4",
    "name": "GI toxicity, follow-up and long term implications [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.4.1.1",
    "name": "GI toxicity, immune related [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.4.1",
    "name": "GI toxicity of anti-CTLA4 antibodies, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.4.2",
    "name": "GI toxicity of anti-PD-1 antibodies, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.4.2.0",
    "name": "GI toxicity of anti-PD-1 antibodies [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.4.3",
    "name": "GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.4.3.0",
    "name": "GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "Gleason grades [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5273_9.0.0.0",
    "name": "Glossary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Glutamine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "GM-CSF [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "Good/intermed. Px, 1st-line treat. [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5273_3.0.0.0",
    "name": "Grading of follicular lymphoma",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5262_6.3.3.8",
    "name": "Gram-negative bacillus, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.10.0",
    "name": "Gram-negative bacillus [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Granisetron [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Granulocyte-colony stimulating factor [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5406_4.1.0.0",
    "name": "Ground glass opacity areas [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5273_5.2.0.0",
    "name": "Groupe d'Etude des lymphomes folliculaires",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5410_3.1.1.0",
    "name": "Grover’s dis­ease [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5275_4.4.0.0",
    "name": "H. pylori eradication, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5410_4.2.6.6",
    "name": "Haematological toxicities, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.6.0",
    "name": "Haematological toxicities [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5263_4.0.0.0",
    "name": "Haematopoietic stem cell transplantation [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5262_6.2.2.0",
    "name": "Haemothorax, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_3.2.0.0",
    "name": "Haemothorax [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5407_3.6.3.0",
    "name": "Haggitt's sub-classification [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5268_3.3.0.0",
    "name": "Half body irradiation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5064_4.5.0.0",
    "name": "HCC, external beam radiotherapy",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_6.0.0.0",
    "name": "HCC, follow-up",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_3.2.0.0",
    "name": "HCC, impact of therapy on prognosis",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.1.0.0",
    "name": "HCC, mgmt. of local disease",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "HCC, pathological diagnosis",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.1.0.0",
    "name": "HCC, radical therapies",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_5.0.0.0",
    "name": "HCC, response evaluation",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_3.3.0.0",
    "name": "HCC, staging and treatment strategy",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.4.0.0",
    "name": "HCC, systemic therapy",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_7.2.0.0",
    "name": "HCC staging, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_7.3.1.0",
    "name": "HCC treatment, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_7.3.4.0",
    "name": "HCC treatment response evaluation, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "HCG [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5263_10.2.1.0",
    "name": "Head & neck radiation, mucositis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5275_7.3.1.0",
    "name": "Helicobacter pylori eradication in MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5086_5.4.2.0",
    "name": "Hemi-thoracic radiotherapy (MPM)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5304_5.5.0.0",
    "name": "Hepatic resection [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "interactive_0001762",
    "name": "Hepatitis management, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.3.2.2",
    "name": "Hepatitis management, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Hepatocellular cancdr, staging",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Hepatocellular cancer, diagnosis",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Hepatojejunostomy [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5277_4.6.0.0",
    "name": "Hepatosplenic T-cell lymphoma (HSTCL)",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5283_4.2.0.0",
    "name": "HER2, human epidermal growth factor receptor 2 (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Hereditary colorectal cancer",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Hereditary diffuse gastric cancer (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "High-dose chemotherapy, prevention [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_5.7.1.0",
    "name": "High-risk patients, overview [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.5.1",
    "name": "High-risk patients, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "High conformal radiation techniques [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Highly emetogenic agents, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Highly emetogenic agents [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5273_5.2.0.0",
    "name": "High tumour burden criteria, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5304_8.6.6.0",
    "name": "HIPEC, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.13.0.0",
    "name": "HIPEC [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5407_3.6.3.0",
    "name": "Histopathology, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_9.2.2.0",
    "name": "Histopathology of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5092_7.3.1.2",
    "name": "Hormone treatment of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5263_4.0.0.0",
    "name": "HSCT [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5277_7.3.4.0",
    "name": "HSTCL in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "Human chorionic gonadotropin [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5282_5.0.0.0",
    "name": "Human epidermal growth factor receptor 2 (HER2)-positive AC (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Hyaluronidase [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Hyperbaric oxygen [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5409_2.0.0.0",
    "name": "Hypersensitivity reaction [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5266_10.4.0.0",
    "name": "Hypertension, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_5.0.0.0",
    "name": "Hypertension [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Hyperthermic intraperitoneal chemotherapy (HIPEC) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "Hypogonadism [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5410_4.2.2.2",
    "name": "Hypophysitis, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001761",
    "name": "Hypophysitis management, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.2.2.2",
    "name": "Hypophysitis management, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.2.2.1",
    "name": "Hypophysitis [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5406_4.1.0.0",
    "name": "IASLC [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5284_7.3.1.2",
    "name": "iCCA, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.2.0",
    "name": "iCCA [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "interactive_0001758",
    "name": "ICPI-related toxicity: management of suspected central neurological toxicity [tool]"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Idarubicin [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5278_3.8.2.0",
    "name": "IELSG score, interactive tool",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.11.0.0",
    "name": "IELSG staging",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "Ifosfamide [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "IHC [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Ileal pouch-anal anastamosis (IPAA)",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Ileorectal anastamosis (IRA)",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_8.6.2.3",
    "name": "Imaging identification of resectable/unresectable disease, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.6.0.0",
    "name": "Imaging identification [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "Imaging in TS",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5285_5.2.2.1",
    "name": "IMDC risk groups",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_5.2.2.2",
    "name": "IMDC score [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5262_6.2.2.0",
    "name": "Immediate complications, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_3.2.0.0",
    "name": "Immediate complications [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5410_4.2.2.1",
    "name": "Immune-related endocrinopathies, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.2.1.1",
    "name": "Immune-related endocrinopathies [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.4.1.1",
    "name": "Immune-related gastrointestinal toxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.3.2.1",
    "name": "Immune-related hepatotoxicity, management [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.3.1",
    "name": "Immune-related hepatotoxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.3.1.0",
    "name": "Immune-related hepatotoxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.5.2.1",
    "name": "Immune-related pneumonitis, management [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.5.1",
    "name": "Immune-related pneumonitis, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.5.2.2",
    "name": "Immune-related pneumonitis mgmt., interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001768",
    "name": "Immune-related pneumonitis mgmt., interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.5.1.0",
    "name": "Immune-related pneumonitis [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5281_5.0.0.0",
    "name": "Immune-related response criteria (irRC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5410_3.1.2.0",
    "name": "Immune-related skin toxicities, diagnosis & pathology [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.1.3.1",
    "name": "Immune-related skin toxicities, grades [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.1.3.1",
    "name": "Immune-related skin toxicities, management of rash [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001760",
    "name": "Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.1.3.3",
    "name": "Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.1.1.0",
    "name": "Immune-related skin toxicities [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.1.1",
    "name": "Immune-related skin toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.1.1.0",
    "name": "Immune-related toxicities [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Immunohistochemical staging",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Immunohistochemistry (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Immunohistochemistry [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5409_11.2.5.0",
    "name": "Immunotherapy [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "Incisional or excisional biopsy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5262_4.3.4.0",
    "name": "Indications, CVC removal",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.3.2",
    "name": "Indications for CVC removal, summary",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5407_4.8.1.0",
    "name": "Indications for postoperative chemoradiotherapy [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5269_4.1.0.0",
    "name": "Indications for primary prophylaxis with G-CSF, overview [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.3.1.0",
    "name": "Indications for primary prophylaxis with G-CSF, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5094_8.0.0.0",
    "name": "Induction chemoradiation therapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5408_4.2.0.0",
    "name": "Induction therapy in stage III non-indolent MCL",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_5.4.0.0",
    "name": "Infusional 5-FU/leucovorin/oxaliplatin (FOLFOX) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5409_11.1.1.0",
    "name": "Infusion reactions, causative drugs [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_2.0.0.0",
    "name": "Infusion reactions, definitions",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_7.0.0.0",
    "name": "Infusion reactions, diagnosis [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_9.0.0.0",
    "name": "Infusion reactions, documentation [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_12.0.0.0",
    "name": "Infusion reactions, follow-up [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_8.1.0.0",
    "name": "Infusion reactions, management [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_5.0.0.0",
    "name": "Infusion reactions, risk assessment [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_6.0.0.0",
    "name": "Infusion reactions, signs and symptoms [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.1.0.0",
    "name": "Infusion reactions, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_4.0.0.0",
    "name": "Infusion reactions, terminology criteria for adverse events [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.1.1",
    "name": "Infusion reactions and anthracyclines, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.1.1",
    "name": "Infusion reactions and chemotherapy, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.2.2",
    "name": "Infusion reactions and cituximab, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.2.1",
    "name": "Infusion reactions and monoclonal antibodies, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.1.2",
    "name": "Infusion reactions and platinum derivatives, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.2.3",
    "name": "Infusion reactions and rituximab, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.1.3",
    "name": "Infusion reactions and taxanes, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.2.5",
    "name": "Infusion reactions and taxanes, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.2.4",
    "name": "Infusion reactions and trastuzumab, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.8.1.1",
    "name": "Infusion reactions causative drugs, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_11.1.1.0",
    "name": "Infusion reactions charact. & mgmt., asso. with chemo drugs [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.1.0.0",
    "name": "Infusion reactions definitions, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.4.0.0",
    "name": "Infusion reactions diagnosis, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.6.0.0",
    "name": "Infusion reactions documentation, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.9.0.0",
    "name": "Infusion reactions follow-up, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_8.3.2.0",
    "name": "Infusion reactions management, interactive tool [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.5.1.0",
    "name": "Infusion reactions management, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "interactive_0001748",
    "name": "Infusion reactions mgmt., interactive tool [IRs]"
  },
  {
    "jumpto": "ENAS5409_13.2.0.0",
    "name": "Infusion reactions risk assessment, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_13.3.0.0",
    "name": "Infusion reactions sign & symptoms, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5269_6.4.2.0",
    "name": "Initial assessment and investigations, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.2.0.0",
    "name": "Initial assessment and investigations [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.4.1",
    "name": "Inpatient oral antibacterial therapy, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.6.1.0",
    "name": "Inpatient oral antibacterial therapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5262_6.2.1.0",
    "name": "Insertion, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_3.1.0.0",
    "name": "Insertion [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5062_4.4.2.0",
    "name": "Intensity-modulated radiotherapy (IMRT) [Anal]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5086_5.4.2.0",
    "name": "Intensity-modulated radiotherapy (IMRT) [MPM]",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "Intensity modulated RT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5280_4.2.4.0",
    "name": "Interferon-α",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5271_4.6.2.0",
    "name": "Interim evaluation, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5270_9.3.2.0",
    "name": "Intermediate-stage cHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5064_7.3.2.0",
    "name": "Intermediate-stage HCC treatment, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5281_4.15.0.0",
    "name": "International association for the study of lung cancer (IASLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "International consortium-developed molecular classification system [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5278_3.5.1.0",
    "name": "International prognostic index, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5271_3.3.0.0",
    "name": "International prognostic index, interactive tool",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5274_3.2.0.0",
    "name": "International scoring system for WM, interactive tool",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5407_4.7.2.6",
    "name": "Interval to surgery [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5269_6.4.6.8",
    "name": "Intra-abdominal or pelvic sepsis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.8.0",
    "name": "Intra-abdominal or pelvic sepsis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_3.2.1.1",
    "name": "Intra-hepatic, cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5407_3.6.4.0",
    "name": "Intra-mesorectal plane [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Intra-operative ultrasound",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Intraductal papillary mucinous neoplasm",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5284_7.3.1.2",
    "name": "Intrahepatic cholangiocarcinoma, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.2.0",
    "name": "Intrahepatic cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Intralesional injection [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5262_6.1.0.0",
    "name": "Introduction, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_6.1.0.0",
    "name": "Introduction, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5284_4.1.0.0",
    "name": "Introduction, treatment [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5262_2.0.0.0",
    "name": "Introduction [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_2.0.0.0",
    "name": "Introduction [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5278_3.5.2.0",
    "name": "IPI & aaIPI, interactive tool",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5410_2.5.0.0",
    "name": "irAEs, baseline assessment",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_2.1.0.0",
    "name": "irAEs, epidemiology",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_2.4.0.0",
    "name": "irAEs, general aspects",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_2.1.0.0",
    "name": "irAEs, overview",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_2.5.0.0",
    "name": "irAEs, patient selection and baseline assessment",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.1.1.0",
    "name": "irAEs epidemiology, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.1.1.0",
    "name": "irAEs general aspects, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Irinotecan [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5263_5.0.0.0",
    "name": "Irinotecan [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Irritants [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Iseganan antimicrobial mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "IV chemotherapy [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Ivor-Lewis procedure, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5282_7.3.1.2",
    "name": "Ivor-Lewis procedure, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Jaundice in introduction(Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Karnofsky performance status (KPS)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5269_5.8.0.0",
    "name": "Key recommendations, FN management",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "KGF-1/palifermin [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5098_6.0.0.0",
    "name": "KIT sequencing [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5284_7.3.1.3",
    "name": "Klatskin tumour, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.3.0",
    "name": "Klatskin tumour [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "KRAS exons [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5407_3.6.3.0",
    "name": "Kudo/Kikuchi (sm)-system [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Laparoscopic gastric mobilisation (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5285_6.1.2.0",
    "name": "Laparoscopic RN [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Laparoscopic surgery, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Laparoscopic surgery recommended option for early gastric cancer, summary",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.2.0.0",
    "name": "Laparoscopy ± peritoneal washings, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "Laparoscopy ± peritoneal washings for malignant cells (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5061_5.2.0.0",
    "name": "Laproscopic colectomy",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5063_2.2.1.0",
    "name": "Large rearrangement analysis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5097_7.3.5.0",
    "name": "Late relapse and toxicity treatment, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5267_6.1.0.0",
    "name": "Later symptoms, extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.5.1.0",
    "name": "Later symptoms, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Lauren classification (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5406_2.0.0.0",
    "name": "LDCT [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5266_3.1.0.0",
    "name": "Left ventricular dysfunction, overview [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.2.1.0",
    "name": "Left ventricular dysfunction, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5285_6.2.2.5",
    "name": "Lenvatinib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5408_3.5.0.0",
    "name": "Leukaemic non-nodal subtype of MCL",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_7.2.2.0",
    "name": "Leukaemic non-nodal subtype of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Level 4 invasion, malignant polyps",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Levels, emetogenicity [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Levels of emetogenicity, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_5.1.0.0",
    "name": "Levomepromazine [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5270_9.3.1.0",
    "name": "Limited-stage cHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Limited disease, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5282_7.3.1.2",
    "name": "Limited disease, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5262_6.3.3.7",
    "name": "Linezolid, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.9.0",
    "name": "Linezolid [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.7.0",
    "name": "Linezolid [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Links staging of HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Liposomal amphotericin B [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Liposomal doxorubicin [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Liquid circulating tumour (ct)DNA biopsies [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.2.2",
    "name": "Liver metastases, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.2.4",
    "name": "Liver metastases, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.7.0.0",
    "name": "Liver metastases [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.2.2.0",
    "name": "Liver metastases [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5064_4.1.0.0",
    "name": "Liver transplantation, HCC radical therapy",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5265_5.1.1.0",
    "name": "LMWH and UFH, acute treatment [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_4.1.0.0",
    "name": "LMWHs enoxaparin [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5407_9.3.1.1",
    "name": "Local.locoregional disease mgmt., summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Local ablative treatments (LAT) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Local damage [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5062_4.3.0.0",
    "name": "Local excision, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5285_5.2.1.1",
    "name": "Localised disease, overview [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.3.0.0",
    "name": "Localised disease, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5282_7.3.1.3",
    "name": "Locally advanced disease, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5285_6.1.3.0",
    "name": "Locally advanced RCC",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.4.1.3",
    "name": "Locally advanced RCC, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5062_4.1.0.0",
    "name": "Local or locoregional disease [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5269_6.4.1.0",
    "name": "Local policies, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.1.0.0",
    "name": "Local policies [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5267_6.3.0.0",
    "name": "Local skin reactions [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "Local thermal ablation [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Local treatments [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "interactive_0001743",
    "name": "Locoregional LN staging, interactive tool [Early NSCLC]"
  },
  {
    "jumpto": "ENAS5406_4.2.0.0",
    "name": "Locoregional LN staging, interactive tool [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_4.3.0.0",
    "name": "Locoregional NSCLC treatment, interactive tool [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Locoregional treatments [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5284_7.5.0.0",
    "name": "Long-term implications, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_6.0.0.0",
    "name": "Long-term implications [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5263_13.0.0.0",
    "name": "Long-term implications [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5265_5.2.0.0",
    "name": "Long-term treatment, solid tumours [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.4.2.0",
    "name": "Long-term treatment in solid tumours, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5061_7.0.0.0",
    "name": "Long term implications, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5285_9.6.0.0",
    "name": "Long term implications, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "Long term implications, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5285_8.0.0.0",
    "name": "Long term implications [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5406_2.0.0.0",
    "name": "Low-dose computed tomography [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Low-level laser therapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5269_5.6.1.0",
    "name": "Low-risk patients, oral therapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.4.1",
    "name": "Low-risk patients, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Low emetogenic potential, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Low emetogenic potential [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5408_3.2.0.0",
    "name": "Lugano classification [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5275_3.0.0.0",
    "name": "Lugano staging system",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5406_4.6.0.0",
    "name": "Lung function test [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5269_6.4.6.4",
    "name": "Lung infiltrates, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Lung infiltrates [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Luteinising hormone (LH) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Lymphadenectomy, extended [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Lymphadenectomy, standard [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_8.3.3.0",
    "name": "Lymphadenectomy in pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5284_4.3.3.0",
    "name": "Lymphadenectomy [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Lymph nodes, infrapyloric [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Lymph nodes, suprpyloric [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5276_4.4.0.0",
    "name": "Lymphoproliferative disorders (LPDs)",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Lynch-associated syndromes",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5063_2.4.0.0",
    "name": "Lynch syndrome, chemoprevention",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Lynch syndrome, definition",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.2.3.0",
    "name": "Lynch syndrome, molecular diagnosis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Lynch syndrome, prevalence",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.4.0.0",
    "name": "Lynch syndrome, prophylactic surgery",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_6.1.1.0",
    "name": "Lynch syndrome, summary",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.3.0.0",
    "name": "Lynch syndrome, surveillance",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_2.4.0.0",
    "name": "Lynch syndrome, treatment",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "M-CAVI [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5086_5.5.3.0",
    "name": "Macroscopic resection, MPM surgery",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Magnetic resonance cholangiopancreatography (MRCP)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Magnetic resonance imaging (MRI) [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5086_4.1.0.0",
    "name": "Magnetic resonance imaging (MRI) [MP]",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Magnetic resonance imaging (MRI) [PC]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Magnetic resonance imaging (MRI) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Magnetic resonance imaging [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5281_4.6.0.0",
    "name": "Maintenance (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.5.0",
    "name": "Maintenance, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_5.14.10.1",
    "name": "Maintenance and second-line treatment options [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.6.0.0",
    "name": "Maintenance therapy (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_8.6.9.0",
    "name": "Maintenance therapy, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.3.0",
    "name": "Maintenance therapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_6.4.2.0",
    "name": "Malignant bowel obstruction, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_5.2.0.0",
    "name": "Malignant bowel obstruction [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "Malignant lymph nodes (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Malignant pleural meothelioma, definition (MPM)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_6.0.0.0",
    "name": "Malignant pleural mesothelioma, follow-up",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Malignant pleural mesothelioma, pathology",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.4.2.0",
    "name": "Malignant pleural mesothelioma, post-op radiotherapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.4.2.0",
    "name": "Malignant pleural mesothelioma, pre-op radiotherapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.4.1.0",
    "name": "Malignant pleural mesothelioma, radiotherapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_4.1.0.0",
    "name": "Malignant pleural mesothelioma, staging",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_4.2.0.0",
    "name": "Malignant pleural mesothelioma, TNM staging",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "Malignant pleural mesothelioma, treatment",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Malignant polyps, treatment",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5262_4.3.2.0",
    "name": "Management, CVC infections",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.1.0.0",
    "name": "Management, FN",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5263_11.1.0.0",
    "name": "Management, overview [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5282_7.4.0.0",
    "name": "Management of advanced/metastatic disease (M1), summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5407_6.1.0.0",
    "name": "Management of advanced/metastatic disease [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5092_7.3.2.1",
    "name": "Management of advanced PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5267_7.1.0.0",
    "name": "Management of extravasation, overview",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.6.1.0",
    "name": "Management of extravasation, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5269_6.4.1.0",
    "name": "Management of FN, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Management of local/locoregional disease (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_7.3.1.1",
    "name": "Management of local/locoregional disease (M0), summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Management of local/locoregional disease, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5094_9.3.1.0",
    "name": "Management of local/locoregional disease, summary [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5285_9.4.1.1",
    "name": "Management of local / locoregional disease, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5407_4.1.0.0",
    "name": "Management of local/locoregional disease [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_9.3.1.1",
    "name": "Management of local/locoregional rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5092_7.3.1.1",
    "name": "Management of local PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.1.0",
    "name": "Management of local PC [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5407_9.4.0.0",
    "name": "Management of local recurrence of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_5.1.0.0",
    "name": "Management of local recurrence [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5285_9.4.2.1",
    "name": "Management of metastatic disease, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Management of metastatic disease, treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5092_4.3.1.0",
    "name": "Management of metastatic PC, overview",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5410_4.2.1.3",
    "name": "Management of rash, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001759",
    "name": "Management of thyroid gland disorders [tool]"
  },
  {
    "jumpto": "ENAS5098_4.2.0.0",
    "name": "Masaoka-Koga staging, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_8.2.0.0",
    "name": "Masaoka-Koga staging system, summary [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_4.3.0.0",
    "name": "Masaoka-‍Koga stage",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5263_11.2.1.0",
    "name": "MASCC/ISOO guidelines, overview [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.10.2.0",
    "name": "MASCC/ISOO guidelines, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5268_3.2.0.0",
    "name": "MASCC antiemetic guidelines [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_6.4.3.0",
    "name": "MASCC index, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.5.0.0",
    "name": "MASCC index [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5408_2.0.0.0",
    "name": "MCL, diagnosis",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_3.3.0.0",
    "name": "MCL, diagnostic work-up",
    "guidelineID": "48"
  },
  {
    "jumpto": "interactive_0001757",
    "name": "MCL therapeutic recom., interactive tool"
  },
  {
    "jumpto": "ENAS5408_4.3.0.0",
    "name": "MCL therapeutic recom., tool",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5268_2.4.1.0",
    "name": "MEC-induced acute nausea and vomiting, prophylaxis",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.4.1",
    "name": "MEC-induced acute nausea and vomiting prophylaxis, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.4.1.0",
    "name": "MEC-induced delayed nausea and vomiting, prophylaxis",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.4.1",
    "name": "MEC-induced delayed nausea and vomiting prophylaxis, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Mechlorethamine [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5098_5.4.0.0",
    "name": "Median sternotomy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5265_4.2.0.0",
    "name": "Medical patients, prevention of VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5269_5.9.6.0",
    "name": "Meropenem [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5407_3.6.4.0",
    "name": "Mesorectal plane [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Mesothelial marker, calretinin",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Mesothelial marker, cytokeratin 5/6",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Mesothelial marker, podplanin (D240)",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_2.0.0.0",
    "name": "Mesothelin",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5285_4.0.0.0",
    "name": "Metabolic RCCs",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Metallic stent [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5283_8.5.0.0",
    "name": "Metastasectomy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Metastasectomy [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_8.6.4.0",
    "name": "Metastases at unfavourable/uncommon sites, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "Metastatic disease, first-line [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.4.0",
    "name": "Metastatic disease, second-line [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.5.0",
    "name": "Metastatic disease, third-line [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_9.4.2.2",
    "name": "Metastatic disease of non-clear cell histology, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Metastatic PC, palliative care [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5071_4.3.1.0",
    "name": "Metastatic SCLC, first-line treatment",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Metastatic SCLC, second-line treatment",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Metastatic TETs, treatment algorithm [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5097_7.3.3.0",
    "name": "Metastatic TS/T-NS treatment, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Methotrexate/carboplatin/vinblastine [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Methotrexate/vinblastine/adriamycin/cisplatin [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5268_2.7.0.0",
    "name": "Metopimazine [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_5.9.8.0",
    "name": "Metronidazole [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5276_7.3.1.0",
    "name": "MF and variants stage I, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.2.0",
    "name": "MF and variants stage IIB, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.3.0",
    "name": "MF and variants stage IV, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5266_3.2.2.0",
    "name": "Mgmt., cardiotoxicity",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_3.4.2.0",
    "name": "Mgmt., trastuzumab cardiotoxicity",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5281_4.1.0.0",
    "name": "Mgmt. of advanced/ metastatic disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_4.2.0.0",
    "name": "Mgmt. of advanced/ metastatic disease (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5281_7.3.1.0",
    "name": "Mgmt. of advanced/ metastatic disease, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5407_9.5.0.0",
    "name": "Mgmt. of advanced/metastatic rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5284_7.3.2.1",
    "name": "Mgmt. of advanced and/or mets. disease, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.4.1.0",
    "name": "Mgmt. of advanced and/or mets. disease [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Mgmt. of advanced and metastatic BC",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5282_4.1.1.0",
    "name": "Mgmt. of local/ locoregional disease (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5284_4.3.1.0",
    "name": "Mgmt. of local/ locoregional disease, overview [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_7.3.1.1",
    "name": "Mgmt. of local/ locoregional disease, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "Mgmt. of local/ locoregional disease, treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5062_8.3.1.0",
    "name": "Mgmt. of local and locoregional anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5094_6.0.0.0",
    "name": "Mgmt. of local disease, interactive tool [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5062_8.3.10.0",
    "name": "Mgmt. of metastatic anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5094_6.0.0.0",
    "name": "Mgmt. of metastatic disease, interactive tool [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5263_14.10.4.0",
    "name": "Mgmt. of mucosal injury caused by cancer Tx, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5266_10.2.4.0",
    "name": "Mgmt. of trastuzumab cardiotoxicity, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5263_14.9.2.2",
    "name": "mIAS, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_10.2.3.0",
    "name": "mIAS [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "MIBC, extended lymphadenectomy",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "MIBC, external beam radiotherapy",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "MIBC, neoadjuvant chemotherapy",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "MIBC, radical cystectomy (RC)",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Microsatellite instability",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_4.2.3.0",
    "name": "Microsatellite instability (MSI)",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.5.3.0",
    "name": "Microsatellite instability, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Microscopic pancreatic intraepithelial",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Milan criteria",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5283_4.5.0.0",
    "name": "miniDOX regimen (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_4.12.0.0",
    "name": "Minimally-invasive procedures in stage IV NSCLC",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.11.0",
    "name": "Minimally-invasive procedures in stage IV NSCLC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Minimally emetogenic, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Minimally emetogenic [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5408_3.4.0.0",
    "name": "MIPI, interactive tool [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_3.1.0.0",
    "name": "MIPI [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Misoprostol mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Misoprostol suppositories [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5062_4.1.0.0",
    "name": "Mitomycin C (MMC)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Mitomycin C [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Mitoxantrone [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "MM-398 [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5063_2.2.1.0",
    "name": "MMR deficiency",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Moderately emetogenic agents, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Moderately emetogenic agents [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Molecular biology, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5263_13.0.0.0",
    "name": "Molecular modelling [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5304_8.2.0.0",
    "name": "Molecular pathology and biomarkers, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.7.0",
    "name": "Molecular profile [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_9.3.0.0",
    "name": "Molecular prognostication, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_5.2.3.0",
    "name": "Molecular prognostication [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5281_4.2.1.0",
    "name": "Molecular test, treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Monitoring, cardiac function after chest RT [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.8.3.0",
    "name": "Monitoring of cardiac func. after chest RT, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.2.3.0",
    "name": "Monoclonal antibodies and targeted agents, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_3.3.0.0",
    "name": "Monoclonal antibodies and targeted agents [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5409_11.2.1.0",
    "name": "Monoclonal antibodies [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5281_4.3.2.0",
    "name": "Monoclonal antibody against EGFR, treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Morphine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "MPM, first-line therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.1.0",
    "name": "MPM, indications for surgery",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "MPM, maintenance therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.2.0",
    "name": "MPM, palliative surgery",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.3.0",
    "name": "MPM, radical surgery",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.2.0.0",
    "name": "MPM, second-line therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.2.0",
    "name": "MPM, surgery for staging",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_5.5.3.0",
    "name": "MPM, surgical procedures definition",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_7.1.0.0",
    "name": "MPM diagnosis, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_7.5.0.0",
    "name": "MPM follow-up, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "MPM subtype, biphasic",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "MPM subtype, epitheloid",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "MPM subtype, sarcomatoid",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5064_5.0.0.0",
    "name": "mRECIST criteria, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "MRI [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "MRI [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "MRI [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5304_4.2.3.0",
    "name": "MSI testing [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_2.0.0.0",
    "name": "mTOR inhibitor-associated stomatitis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Mucinous cystic neoplasm (Pancreatic Cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Mucinous lesions (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5263_10.2.1.0",
    "name": "Mucositis, chemotherapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_10.2.1.0",
    "name": "Mucositis, head & neck radiation [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.1.0.0",
    "name": "Mucositis, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.9.2.1",
    "name": "Mucositis caused by chemotherapy, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.9.2.1",
    "name": "Mucositis caused by head & neck radiation, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_2.0.0.0",
    "name": "Mucositis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "MUGA scan [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Muir-Torre syndrome",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5263_5.0.0.0",
    "name": "Multi-cycle chemotherapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Multidisciplinary treatment planning, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "Multiparametric MRI [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5268_2.5.0.0",
    "name": "Multiple-day cisplatin ChT, prev. [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Multiple-phase multidetector CT scan",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Multiple gated acquisition scan [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Multiplex polymerase chain reaction (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Multiplex systems (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "Muscle-invasive BC, treatment",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Muscle-invasive bladder cancer (MIBC)",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5407_3.6.4.0",
    "name": "Muscularis propria plane [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5063_5.4.0.0",
    "name": "MUTYH-associated polyposis, chemoprevention",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_5.1.0.0",
    "name": "MUTYH-associated polyposis, definition",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_5.2.0.0",
    "name": "MUTYH-associated polyposis, diagnosis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_5.6.0.0",
    "name": "MUTYH-associated polyposis, follow-up",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_5.1.0.0",
    "name": "MUTYH-associated polyposis, prevalence",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_6.4.1.0",
    "name": "MUTYH-associated polyposis, summary",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_5.3.0.0",
    "name": "MUTYH-associated polyposis, surveillance",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.2.2.0",
    "name": "MUTYH associated polyposis (MAP)",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5063_4.2.2.0",
    "name": "MUTYH germline analysis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "MVAC [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5098_7.0.0.0",
    "name": "Myasthenic crisis [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5276_4.2.0.0",
    "name": "Mycosis fungoides (MF)",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Nanoliposomal irinotecan [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5268_5.3.0.0",
    "name": "Nausea and vomiting, opioid-induced",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.4.2.0",
    "name": "Nausea and vomiting in malignant bowel obstruction, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_14.8.2.0",
    "name": "NCI-CTCAE, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_9.2.0.0",
    "name": "NCI-CTCAE scale [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5281_4.3.2.0",
    "name": "Necitumumab an immunoglobulin G1, treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Needle aspiration biopsy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.4.1.0",
    "name": "Neo-adjuvant chemotherapy, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_4.2.2.0",
    "name": "Neoadjuvant ADT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5094_9.3.3.0",
    "name": "Neoadjuvant and adjuvant therapy in BC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.3.0.0",
    "name": "Neoadjuvant chemotherapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "Neoadjuvant chemotherapy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5282_5.0.0.0",
    "name": "Neoadjuvant treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Neoadjuvant treatment [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Neoadjuvant [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Neoplasia [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Neoplastic polyp",
    "guidelineID": "10"
  },
  {
    "jumpto": "interactive_0001764",
    "name": "Nephritis management, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.6.4.2",
    "name": "Nephritis management, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Netupitant [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5410_4.2.6.1",
    "name": "Neurological toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.1.1",
    "name": "Neurological toxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "Neurotoxicity [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "New onset diabetes (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Next-generation sequencing, NGS (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "Nivolumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Nivolumab, Second-line treatment in NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.2.0",
    "name": "Nivolumab, Second-line treatment in SCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "Nivolumab second-line treatment in NSCC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_6.2.2.6",
    "name": "Nivolumab [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5268_2.2.4.0",
    "name": "NK1 RAs, differences [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.4.0",
    "name": "NK1 receptor antagonists, doses [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5277_2.0.0.0",
    "name": "Nodal and extranodal PTCL subtypes",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5071_4.2.0.0",
    "name": "Nodal dissection",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Nodal dissection [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5277_4.3.0.0",
    "name": "Nodal PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5277_7.3.1.0",
    "name": "Nodal PTCLs in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5285_6.2.2.7",
    "name": "Non-clear cell histology, treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Non-DNA-binding compounds [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5062_2.1.0.0",
    "name": "Non-healing ulcer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5064_2.0.0.0",
    "name": "Non-invasive criteria, hepatocellular cancer",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5094_4.1.0.0",
    "name": "Non-muscle-invasive BC, treatment",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_4.1.0.0",
    "name": "Non-muscle-invasive bladder cancer (NIBC)",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Non-vesicant [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "NRAS exons [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_7.3.2.3",
    "name": "NSCC first-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "NSCC second-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5406_7.0.0.0",
    "name": "NSCLC, follow-up and long term implications [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_6.0.0.0",
    "name": "NSCLC, personalised medicine [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.3.4.0",
    "name": "NSCLC, pretreatment risk assessment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_4.1.0.0",
    "name": "NSCLC, staging and risk assessment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.1.0.0",
    "name": "NSCLC, summary of recommendations [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.2.0.0",
    "name": "NSCLC diagnosis and pathology, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_3.0.0.0",
    "name": "NSCLC early, diagnosis",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.7.0.0",
    "name": "NSCLC follow-up, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_4.5.0.0",
    "name": "NSCLC locally advanced (stage III), staging [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.2.1.0",
    "name": "NSCLC locally advanced (stage III), treatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.3.3.0",
    "name": "NSCLC locally advanced (stage III) staging, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.5.1.0",
    "name": "NSCLC locally advanced (stage III) systemic therapy, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.5.1.0",
    "name": "NSCLC locally advanced (stage III) treatment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.3.2.0",
    "name": "NSCLC locoregional staging, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.6.0.0",
    "name": "NSCLC personalised medicine, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.5.2.0",
    "name": "NSCLC resectable locally advanced (stage III) treatment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.2.2.0",
    "name": "NSCLC resectable locally advanced, treatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.5.0",
    "name": "NSCLC stages I and II, postoperative radiotherapy [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.4.0",
    "name": "NSCLC stages I and II, radiofrequency ablation [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.3.0",
    "name": "NSCLC stages I and II, radiotherapy treatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.1.0",
    "name": "NSCLC stages I and II, surgical treatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.2.0",
    "name": "NSCLC stages I and II, systemic therapy [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.4.5.0",
    "name": "NSCLC stages I and II postop radiotherapy, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.4.3.0",
    "name": "NSCLC stages I and II primary radiotherapy treatment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.4.4.0",
    "name": "NSCLC stages I and II radiofrequency ablation, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.4.1.0",
    "name": "NSCLC stages I and II surgical treatment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.4.2.0",
    "name": "NSCLC stages I and II systemic therapy, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.3.1.0",
    "name": "NSCLC staging and risk assessment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_8.5.3.0",
    "name": "NSCLC unresectable locally advanced (stage III) treatment, summary [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.2.3.0",
    "name": "NSCLC unresectable locally advanced, treatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5282_3.1.0.0",
    "name": "Nutritional status (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5061_5.2.0.0",
    "name": "Obstructive colorectal cancer, treatment",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5265_3.0.0.0",
    "name": "Occult cancer idiopathic VTE, diagnosis",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.2.0.0",
    "name": "Occult cancer idiopathic VTE diagnosis, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5281_3.3.0.0",
    "name": "Occult carcinoma (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Octreotide [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5410_4.2.6.5",
    "name": "Ocular toxicities, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.5.0",
    "name": "Ocular toxicities [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Oesophageal varices, HCC staging",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5275_3.0.0.0",
    "name": "Oesophagogastroduodenoscopy",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5268_6.1.3.2",
    "name": "Olanzapine, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.3.5.0",
    "name": "Olanzapine [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Oligometastatic disease (OMD) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.2.1",
    "name": "Oligometastatic disease, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.4.0.0",
    "name": "Oncological criteria [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5275_4.5.0.0",
    "name": "Oncological therapy, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5275_7.3.2.0",
    "name": "Oncological therapy in MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5268_2.3.2.0",
    "name": "Ondansetron [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_5.3.0.0",
    "name": "Opioid-induced, nausea and vomiting",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.4.3.0",
    "name": "Opioid-induced nausea and vomiting, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_5.3.0.0",
    "name": "Opioid rotation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_14.3.0.0",
    "name": "Oral and GI mucositis in HSCT, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_4.0.0.0",
    "name": "Oral and GI mucositis in HSCT [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Oral cavity mucositis guideline [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Oral chemotherapy [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Oral cryotherapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_3.0.0.0",
    "name": "Oral mucositis, head and neck radiation [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.8.2.0",
    "name": "Oral mucositis grading, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_9.2.0.0",
    "name": "Oral mucositis grading [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.2.0.0",
    "name": "Oral mucositis in head and neck radiation, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5269_5.6.1.0",
    "name": "Oral quinolone therapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.6.1.0",
    "name": "Oral therapy, low-risk patients [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.4.1",
    "name": "Oral therapy, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Organising fibrinous exudates",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5094_6.0.0.0",
    "name": "Organ preservation therapy, interactive tool [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5094_9.3.4.0",
    "name": "Organ preservation therapy in BC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Osteoma",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5268_6.1.2.4",
    "name": "Other highly emetogenic ChT, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.2.5.0",
    "name": "Other highly emetogenic ChT [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5270_5.2.0.0",
    "name": "Other stages of NLPHL, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.4.2.0",
    "name": "Other stages of NLPHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "Ototoxicity [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5269_6.4.3.0",
    "name": "Outcome risk assessment, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.3.0.0",
    "name": "Outcome risk assessment [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.4.2",
    "name": "Outpatient and early discharge policies, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.6.2.0",
    "name": "Outpatient and early discharge policies [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5285_5.2.2.1",
    "name": "Overview, advanced disease [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5266_3.2.1.0",
    "name": "Overview, anthracyclines and cytotoxics [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5268_5.1.0.0",
    "name": "Overview, antiemetics in advanced cancer [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5266_9.1.0.0",
    "name": "Overview, cardiac toxicity induced by RT [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5262_5.1.0.0",
    "name": "Overview, catheter-induced thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5267_9.1.0.0",
    "name": "Overview, central venous access device extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5266_3.2.1.0",
    "name": "Overview, cumulative dose-related cardiotoxicity [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5262_4.1.0.0",
    "name": "Overview, CVC-related infection",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.7.1.0",
    "name": "Overview, high-risk patients [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.1.0.0",
    "name": "Overview, indications for primary prophylaxis with G-CSF [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5266_3.1.0.0",
    "name": "Overview, left ventricular dysfunction [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5285_5.2.1.1",
    "name": "Overview, localised disease [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5267_7.1.0.0",
    "name": "Overview, management of extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5263_11.1.0.0",
    "name": "Overview, management [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.1.0",
    "name": "Overview, MASCC/ISOO guidelines [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5284_4.3.1.0",
    "name": "Overview, mgmt. of local/ locoregional disease [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5268_2.2.1.0",
    "name": "Overview, prevention by emetogenic ChT [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.4.1.0",
    "name": "Overview, prevention by MEC [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_3.1.0.0",
    "name": "Overview, prevention of RINV [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_10.1.0.0",
    "name": "Overview, preventive measures [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_6.2.2.1",
    "name": "Overview, systemic treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5266_3.4.1.0",
    "name": "Overview, trastuzumab cardiotoxicity",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.8.1.0",
    "name": "Overview of cardiac toxicity induced by RT, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5262_6.4.1.0",
    "name": "Overview of catheter-induced thrombosis, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.1.0",
    "name": "Overview of CVC-related infection, summary",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5266_10.2.1.0",
    "name": "Overview of left ventricular dysfunction, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5263_14.10.1.0",
    "name": "Overview of management, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.9.1.0",
    "name": "Overview of preventive measures, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Oxaliplatin, metastatic pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5268_6.1.4.3",
    "name": "Oxaliplatin, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.4.3.0",
    "name": "Oxaliplatin [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Oxaliplatin [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Paclitaxel (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Paclitaxel, metastatic pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "Paclitaxel/carboplatin [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "Paclitaxel/cisplatin/5-fluorouracil [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "Paclitaxel/cisplatin/ifosfamide [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5094_5.1.0.0",
    "name": "Paclitaxel plus [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "Paclitaxel [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Paclitaxel [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Pain management [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5062_8.3.11.0",
    "name": "Palliative care in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_7.3.3.0",
    "name": "Palliative care in metastatic PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5281_4.13.0.0",
    "name": "Palliative care in stage IV NSCLC",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.12.0",
    "name": "Palliative care in stage IV NSCLC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_4.2.0.0",
    "name": "Palliative chemotherapy (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5304_7.0.0.0",
    "name": "Palliative chemotherapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.11.0.0",
    "name": "Palliative surgery in stage IV NSCLC",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.10.0",
    "name": "Palliative surgery in stage IV NSCLC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_4.2.0.0",
    "name": "Palliative treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Palonosetron [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5068_5.5.0.0",
    "name": "Pancreatic cancer, adjuvant treatment",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Pancreatic cancer, advanced",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Pancreatic cancer, biology",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Pancreatic cancer, Borderline resectable",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Pancreatic cancer, diagnosis",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Pancreatic cancer, diagnostic work-up",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_7.0.0.0",
    "name": "Pancreatic cancer, follow-up",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.6.2.0",
    "name": "Pancreatic cancer, locally advanced",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_7.0.0.0",
    "name": "Pancreatic cancer, long-term implications",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Pancreatic cancer, lymphadenectomy",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Pancreatic cancer, metastatic",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Pancreatic cancer, metastatic disease",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Pancreatic cancer, oncological treatment",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Pancreatic cancer, palliative care",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Pancreatic cancer, pathology",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_6.0.0.0",
    "name": "Pancreatic cancer, personalised medicine",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Pancreatic cancer, resectable",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_3.0.0.0",
    "name": "Pancreatic cancer, staging and assessment",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_8.1.0.0",
    "name": "Pancreatic cancer, summary of recommendations",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Pancreatic cancer, supportive care",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_4.2.0.0",
    "name": "Pancreatic cancer, TNM classification",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.1.0.0",
    "name": "Pancreatic cancer, treatment strategy",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.2.0.0",
    "name": "Pancreatic cancer, treatment summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_8.3.1.0",
    "name": "Pancreatic cancer, treatment summary recommendations",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Pancreatic cancers, adenocarcinoma",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Pancreatic cancers, ductal adenocarcinoma",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5068_5.4.0.0",
    "name": "Pancreatoduodenectomy",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5086_3.0.0.0",
    "name": "Pancytokeratin markers",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "Panitumumab [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_2.0.0.0",
    "name": "Paraneoplastic syndromes [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5275_3.0.0.0",
    "name": "Paris staging system",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "Partial nephrectomy [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5407_4.7.2.5",
    "name": "Pathological assessment of response [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Pathological tumour node metastasis (pTNM) system",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5283_2.0.0.0",
    "name": "Pathology (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Pathology, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5284_7.1.0.0",
    "name": "Pathology, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5282_2.0.0.0",
    "name": "Pathology/molecular biology (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5406_3.0.0.0",
    "name": "Pathology/molecular biology, early NSCLC",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5273_2.0.0.0",
    "name": "Pathology/molecular biology, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_2.1.0.0",
    "name": "Pathology/molecular biology, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5282_7.1.0.0",
    "name": "Pathology/molecular biology, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5263_14.7.0.0",
    "name": "Pathology/ molecular biology, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5273_8.1.0.0",
    "name": "Pathology/molecular biology of FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.1.0.0",
    "name": "Pathology/molecular biology of HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5408_7.1.0.0",
    "name": "Pathology/molecular biology of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_2.0.0.0",
    "name": "Pathology/molecular biology [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5263_8.0.0.0",
    "name": "Pathology/ molecular biology [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_9.2.0.0",
    "name": "Pathology assessment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Pathology assessment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5086_7.2.0.0",
    "name": "Pathology of MPM, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5092_7.1.0.0",
    "name": "Pathology of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5284_2.0.0.0",
    "name": "Pathology [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5267_12.3.0.0",
    "name": "Patient-related risk factors, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Patient-related risk factors [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5269_6.4.1.0",
    "name": "Patient education, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.1.0.0",
    "name": "Patient education [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_4.1.2.0",
    "name": "Patient selection and baseline assessment, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Patients with sensitive disease [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "Pazopanib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5092_4.2.1.0",
    "name": "PC, advantages and disadvantages of treatment",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "PC, androgen-deprivation therapy (ADT)",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "PC, classification",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.4.0",
    "name": "PC, continuous ADT",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "PC, diagnosis",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "PC, follow-up and long term implications",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.2.0",
    "name": "PC, hormone treatment in local disease",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.4.0",
    "name": "PC, intermittent ADT",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.1.0",
    "name": "PC, management of local disease",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.1.0",
    "name": "PC, management of metastatic disease",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_5.0.0.0",
    "name": "PC, personalised medicine",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.3.0",
    "name": "PC, post-operative RT in local disease",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "PC, risk assessment",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.3.0.0",
    "name": "PC, risk groups",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "PC, staging",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_7.1.0.0",
    "name": "PC, summary recommendations",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "PC, therapeutic strategies",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.2.0.0",
    "name": "PC, TNM staging",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "PC, treatment of CRPC",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.2.4.0",
    "name": "PC, treatment of relapse",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5284_7.3.1.3",
    "name": "pCCA, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.3.0",
    "name": "pCCA [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "PC metastatic, palliative care",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "PCR, diagnosis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "PCR, polymerase chain reaction (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Pedunculated polypoid carcinoma",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "Pegfilgrastim, dose [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "Pegfilgrastim, route of application [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.3.0.0",
    "name": "Pegfilgrastim, schedule [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Pelvic MRI [Anal cancer]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "Pembrolizumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Pembrolizumab, Second-line treatment in NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.2.0",
    "name": "Pembrolizumab, Second-line treatment in SCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "Pembrolizumab second-line treatment in NSCC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "Pemetrexed, MPM therapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Pemetrexed, Second-line treatment in NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.3.3.0",
    "name": "Pemetrexed-based combination chemotherapy (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.3",
    "name": "Pemetrexed second-line treatment in NSCC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.6.0.0",
    "name": "Pemetrexed switch maintenance (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5096_4.2.0.0",
    "name": "PenCa, brachytherapy",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.3.0.0",
    "name": "PenCa, chemoradiotherapy",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "PenCa, chemotherapy",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.5.0.0",
    "name": "PenCa, chemotherapy for advanced disease",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.4.0.0",
    "name": "PenCa, combination chemotherapy",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_2.1.0.0",
    "name": "PenCa, diagnosis",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_2.2.0.0",
    "name": "PenCa, diagnosis guidelines",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_6.1.0.0",
    "name": "PenCa, follow-up",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_6.2.0.0",
    "name": "PenCa, follow-up of local recurrence",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_6.3.0.0",
    "name": "PenCa, follow-up of regional recurrence",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_5.0.0.0",
    "name": "PenCa, personalised medicine",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.2.0.0",
    "name": "PenCa, radiotherapy",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.1.0",
    "name": "PenCa, recommendations for treatment",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_3.1.0.0",
    "name": "PenCa, risk factors",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_3.1.0.0",
    "name": "PenCa, risk groups",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_3.1.0.0",
    "name": "PenCa, staging and risk assessment",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.1.0.0",
    "name": "PenCa, surgical treatment",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_3.2.0.0",
    "name": "PenCa, TNM staging",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.5.0",
    "name": "PenCa, treat. algo. for regional lymph node [Interactive tool]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.3.0",
    "name": "PenCa, treat. algorithm of primary tumour",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.4.0",
    "name": "PenCa, treatment for regional lymph nodes",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.7.0",
    "name": "PenCa, treatment of metastatic disease",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.2.0",
    "name": "PenCa, treatment of primary tumour",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.6.6.0",
    "name": "PenCa, treatment strategies for recurrence",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_4.1.0.0",
    "name": "Penectomy, effects on QoL [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_6.2.0.0",
    "name": "Penectomy, in local recurrence [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5096_6.2.0.0",
    "name": "Penile-preserving treatment [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5280_4.2.3.0",
    "name": "Pentostatin",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Pentoxifylline [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5284_3.2.1.2",
    "name": "Peri-hilar, cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_3.1.0.0",
    "name": "Peri-hilar cholangiocarcinoma, Bismuth-Corlette classification [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Pericarditis [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5284_7.3.1.3",
    "name": "Perihilar cholangiocarcinoma, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.3.3.0",
    "name": "Perihilar cholangiocarcinoma [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5062_4.9.0.0",
    "name": "Perineal reconstruction",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5283_4.3.2.0",
    "name": "Perioperative chemotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.2",
    "name": "Perioperative chemotherapy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5304_5.14.6.0",
    "name": "Perioperative chemotherapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5283_4.3.2.0",
    "name": "Perioperative trastuzumab therapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5267_7.4.0.0",
    "name": "Peripheral line extravasation, steps",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5262_6.2.1.0",
    "name": "Peripherally inserted central catheters, summary[CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_3.1.0.0",
    "name": "Peripherally inserted central catheters [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5410_3.6.1.2",
    "name": "Peripheral neurological symptoms, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.1.3",
    "name": "Peripheral neurological syndromes, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001769",
    "name": "Peripheral neurological toxicity mgmt-2., interactive tool [irAEs]"
  },
  {
    "jumpto": "interactive_0001766",
    "name": "Peripheral neurological toxicity mgmt., interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5283_8.5.0.0",
    "name": "Peritoneal metastases, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5304_8.6.6.0",
    "name": "Peritoneal metastases, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.13.0.0",
    "name": "Peritoneal metastases [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Peritonectomy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5282_5.0.0.0",
    "name": "Personalised medicine (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5062_4.10.0.0",
    "name": "Personalised medicine, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5279_5.0.0.0",
    "name": "Personalised medicine, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_6.0.0.0",
    "name": "Personalised medicine, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_5.0.0.0",
    "name": "Personalised medicine, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_6.0.0.0",
    "name": "Personalised medicine, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5273_6.0.0.0",
    "name": "Personalised medicine, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_5.0.0.0",
    "name": "Personalised medicine, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_7.0.0.0",
    "name": "Personalised medicine, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_5.0.0.0",
    "name": "Personalised medicine, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5276_5.0.0.0",
    "name": "Personalised medicine, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5277_5.0.0.0",
    "name": "Personalised medicine, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5071_4.4.0.0",
    "name": "Personalised medicine, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5281_7.1.0.0",
    "name": "Personalised medicine, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_7.5.0.0",
    "name": "Personalised medicine, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5284_7.4.0.0",
    "name": "Personalised medicine, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5304_8.7.0.0",
    "name": "Personalised medicine, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_14.11.0.0",
    "name": "Personalised medicine, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_9.5.0.0",
    "name": "Personalised medicine, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5407_9.6.0.0",
    "name": "Personalised medicine, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5098_6.0.0.0",
    "name": "Personalised medicine, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_5.0.0.0",
    "name": "Personalised medicine, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5283_5.0.0.0",
    "name": "Personalised medicine and targeted therapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.4.0.0",
    "name": "Personalised medicine and targeted therapy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5062_8.3.9.0",
    "name": "Personalised medicine in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5094_9.5.0.0",
    "name": "Personalised medicine in BC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5279_7.4.0.0",
    "name": "Personalised medicine in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_7.5.0.0",
    "name": "Personalised medicine in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.4.0.0",
    "name": "Personalised medicine in DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_8.4.4.0",
    "name": "Personalised medicine in early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5273_8.4.0.0",
    "name": "Personalised medicine in FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.4.0.0",
    "name": "Personalised medicine in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_9.6.0.0",
    "name": "Personalised medicine in HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.4.0.0",
    "name": "Personalised medicine in MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5408_7.4.0.0",
    "name": "Personalised medicine in MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5068_8.4.0.0",
    "name": "Personalised medicine in pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5092_7.4.0.0",
    "name": "Personalised medicine in PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5096_7.4.0.0",
    "name": "Personalised medicine in PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5277_7.4.0.0",
    "name": "Personalised medicine in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5098_8.4.0.0",
    "name": "Personalised medicine in TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_7.4.0.0",
    "name": "Personalised medicine in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "Personalised medicine synopsis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5283_5.0.0.0",
    "name": "Personalised medicine synopsis table (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_5.0.0.0",
    "name": "Personalised medicine synopsis table (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5094_7.0.0.0",
    "name": "Personalised medicine [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5284_5.0.0.0",
    "name": "Personalised medicine [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5408_5.0.0.0",
    "name": "Personalised medicine [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_6.0.0.0",
    "name": "Personalised medicine [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_12.0.0.0",
    "name": "Personalised medicine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_7.0.0.0",
    "name": "Personalised medicine [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5407_7.0.0.0",
    "name": "Personalised medicine [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5071_6.4.0.0",
    "name": "Personlised medicine in SCLC, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "PET-CT imaging (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "PET/CT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5278_3.3.0.0",
    "name": "PET 5-point scale, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Peutz-Jeghers syndrome",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5096_4.1.0.0",
    "name": "Phalloplasty [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "Phosphatase and tensin homologue (PTEN) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5098_5.4.0.0",
    "name": "Phrenic nerve preservation [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5062_4.3.0.0",
    "name": "Piecemeal resection",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "PIK3CA exon [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Pilocarpine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Platin salts [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5282_4.1.6.0",
    "name": "Platinum, treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5281_4.5.0.0",
    "name": "Platinum-based chemotherapy (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5094_4.3.0.0",
    "name": "Platinum-based combination chemotherapy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5283_4.3.2.0",
    "name": "Platinum/fluoropyrimidine combination chemotherapy (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.2",
    "name": "Platinum/fluoropyrimidine combination chemotherapy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5409_11.1.3.0",
    "name": "Platinum derivatives [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5086_5.3.0.0",
    "name": "Platinum doublet, unresectable mesothelioma",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5269_5.9.3.0",
    "name": "Pneumocystis jirovecii [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.3",
    "name": "Pneumonia, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.3.0",
    "name": "Pneumonia [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_3.5.1.0",
    "name": "Pneumonitis, immune related [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.5.2.2",
    "name": "Pneumonitis mgmt., interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "interactive_0001768",
    "name": "Pneumonitis mgmt., interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5262_6.2.2.0",
    "name": "Pneumothorax, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_3.2.0.0",
    "name": "Pneumothorax [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5063_4.2.2.0",
    "name": "Polyposis syndromes, genetic diagnosis",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5285_6.2.2.4",
    "name": "Poor prognosis, first-line treat. [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Portal hypertension, HCC staging",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5406_5.1.5.0",
    "name": "PORT [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Positron-emission tomography (PET)/CT",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5098_8.3.4.0",
    "name": "Post-op chemotherapy in TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5062_8.3.6.0",
    "name": "Post-operative chemoradiotherapy in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_7.3.1.3",
    "name": "Post-operative radiotherapy of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "Post-op radiotherapy, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_8.3.3.0",
    "name": "Post-op radiotherapy in TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Post-orchiectomy staging [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5271_4.6.1.0",
    "name": "Post-treatment evaluation, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5407_4.8.1.0",
    "name": "Postoperative chemoradiotherapy [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.8.2.0",
    "name": "Postoperative chemotherapy [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_9.3.6.0",
    "name": "Postoperative therapy, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5267_12.2.0.0",
    "name": "Potential for anticancer agents, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Potential for anticancer agents [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_5.14.6.0",
    "name": "Potentially curative surgery [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Prednisolone [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "interactive_0001745",
    "name": "Preoperative cardiac evaluation, interactive tool [Early NSCLC]"
  },
  {
    "jumpto": "ENAS5406_4.9.0.0",
    "name": "Preoperative cardiac evaluation, interactive tool [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5407_9.3.5.1",
    "name": "Preoperative chemotherapy, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "interactive_0001744",
    "name": "Preoperative respiratory evaluation, interactive tool [Early NSCLC]"
  },
  {
    "jumpto": "ENAS5406_4.7.0.0",
    "name": "Preoperative respiratory evaluation, interactive tool [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_4.6.0.0",
    "name": "Pretreatment risk assessment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5268_2.8.0.0",
    "name": "Prev., anticipatory nausea and vomiting",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.6.0.0",
    "name": "Prev., ChT with low & minimal emetogenic potential [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.5.0.0",
    "name": "Prev., multiple-day cisplatin ChT [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.6.0",
    "name": "Prev. by ChT with low & min. emetogenic pot., summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.5.0",
    "name": "Prev. by multiple-day cisplatin ChT, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.8.0",
    "name": "Prev. of anticipatory nausea and vomiting, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_4.0.0.0",
    "name": "Prevention, acute CINV in children [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_5.6.0.0",
    "name": "Prevention, catheter-induced thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.5.2.0",
    "name": "Prevention, catheter-related thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Prevention, CINV",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_4.4.0.0",
    "name": "Prevention, CVC-related infections",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5267_5.0.0.0",
    "name": "Prevention, extravasation [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "Prevention, high-dose chemotherapy [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5267_12.4.0.0",
    "name": "Prevention, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5268_2.2.1.0",
    "name": "Prevention by emetogenic ChT, overview [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.9.0",
    "name": "Prevention by high-dose chemotherapy, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.2.1",
    "name": "Prevention by highly emetogenic ChT, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_2.4.1.0",
    "name": "Prevention by MEC, overview [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.1.4.1",
    "name": "Prevention by MEC, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.3.0.0",
    "name": "Prevention of acute CINV in children, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_6.4.5.0",
    "name": "Prevention of catheter-induced thrombosis, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.4.0",
    "name": "Prevention of CVC-related infections, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5268_3.1.0.0",
    "name": "Prevention of RINV, overview [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_6.2.1.0",
    "name": "Prevention of RINV, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5265_4.2.0.0",
    "name": "Prevention of VTE, medical patients",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_4.1.0.0",
    "name": "Prevention of VTE, surgical patients",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.3.2.0",
    "name": "Prevention of VTE in medical patients, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.3.1.0",
    "name": "Prevention of VTE in surgical patients, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5263_10.1.0.0",
    "name": "Preventive measures, overview [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5098_8.3.6.0",
    "name": "Primary/induction chemotherapy, summary [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5062_4.3.0.0",
    "name": "Primary abdomino-perineal excision (APE)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5278_2.4.0.0",
    "name": "Primary central nervous system lymphoma (PCNSL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Primary chemoprevention [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5276_4.4.0.0",
    "name": "Primary cutaneous CD30-positive LPDs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.5.0",
    "name": "Primary cutaneous CD30-positive LPDs, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_4.7.0.0",
    "name": "Primary cutaneous PTCL-NOS",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.8.0",
    "name": "Primary cutaneous PTCL-NOS, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5278_2.6.0.0",
    "name": "Primary diffuse large B-cell lymphoma of the bone (PBoL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_2.5.0.0",
    "name": "Primary diffuse large B-cell lymphoma of the breast (PBL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5269_4.2.0.0",
    "name": "Primary G-CSF prophylaxis, algo. [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5278_2.2.0.0",
    "name": "Primary mediastinal large B-cell lymphoma (PMBCL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5096_4.6.3.0",
    "name": "Primary penile tumour, treatment algorithm [Interactive tool]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5269_6.3.1.0",
    "name": "Primary prophylaxis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.1.0.0",
    "name": "Primary prophylaxis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5278_2.3.0.0",
    "name": "Primary testicular lymphoma (PTL)",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5281_3.2.0.0",
    "name": "Primary tumour (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Probiotics [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5267_12.3.0.0",
    "name": "Procedure-related risk factors, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Procedure-related risk factors [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Proctocolectomy",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Proctoscopy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Proctoscopy, risk assessment",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5270_6.0.0.0",
    "name": "Prognosis, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.5.0.0",
    "name": "Prognosis of HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5281_3.3.0.0",
    "name": "Prognostic groups (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5061_4.3.0.0",
    "name": "Prognostic groups, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5097_4.5.2.0",
    "name": "Prognostic score, relapsing TS/ T-NS",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5071_4.2.0.0",
    "name": "Prophylactic cranial irradiation (PCI)[SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "Prophylactic irradiation [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5263_11.3.0.0",
    "name": "Prophylactic systematic gastrostomy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "Prostate specific antigen",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5281_4.4.0.0",
    "name": "PS 2 and beyond (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.3.0",
    "name": "PS 2 and beyond, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5092_6.0.0.0",
    "name": "PSA, PC follow-up [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_3.1.0.0",
    "name": "PSA in risk assessment of PC",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "PSA [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5283_7.0.0.0",
    "name": "Psychological support, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.6.0.0",
    "name": "Psychological support, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "PTA and BCoG [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5277_4.2.0.0",
    "name": "PTCL Mgmt.: Front-line & relapsed, interactive tool",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "Pulmonary [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5266_10.5.0.0",
    "name": "QT prolongation, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_6.0.0.0",
    "name": "QT prolongation [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5062_8.4.0.0",
    "name": "Quality of life in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "Radiation techniques [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Radiation therapy oncology group (RTOG)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_4.4.2.0",
    "name": "Radiation Therapy Oncology Group (RTOG)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "Radical cystectomy [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Radical gastrectomy, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Radical gastrectomy in stage IB–III gastric cancer, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Radical oesophagectomy, surgical technique (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5064_6.0.0.0",
    "name": "Radical treatment for HCC, follow-up",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Radioembolisation, with glass",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Radioembolisation, with resin yttrium-90",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "Radioembolisation [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Radiofrequency ablation (RFA) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "Radiofrequency ablation [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_2.0.0.0",
    "name": "Radiological imaging [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Radiotherapy, advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5098_5.9.0.0",
    "name": "Radiotherapy, definitive [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5068_5.6.2.0",
    "name": "Radiotherapy, locally advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "Radiotherapy, post-op [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5277_4.7.0.0",
    "name": "Radiotherapy, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Radiotherapy, role [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5284_7.3.2.1",
    "name": "Radiotherapy, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5285_9.4.2.3",
    "name": "Radiotherapy, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5062_4.8.0.0",
    "name": "Radiotherapy, supportive care",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_4.8.0.0",
    "name": "Radiotherapy, toxicity",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5266_9.3.0.0",
    "name": "Radiotherapy-related cardiac complications, Tx [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5268_3.2.0.0",
    "name": "Radiotherapy emetic risk levels [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5407_9.3.4.0",
    "name": "Radiotherapy field sizes, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.6.0.0",
    "name": "Radiotherapy field sizes [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5086_7.4.3.1",
    "name": "Radiotherapy in MPM, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5096_7.3.2.0",
    "name": "Radiotherapy in PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5277_7.3.5.0",
    "name": "Radiotherapy in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5284_4.4.1.0",
    "name": "Radiotherapy [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Radiotherapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5068_5.6.1.0",
    "name": "Radiotherapy [Pancr]",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5096_4.2.0.0",
    "name": "Radiotherapy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "Radiotherapy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "Radiotherapy [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Radium-223 [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Radium-223, side effects [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5279_3.2.0.0",
    "name": "RAI system [CLL]",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5086_5.1.0.0",
    "name": "Raltitrexed, MPM therapy, Combination doublet chemotherapy",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "Ramucirumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5410_4.2.6.1",
    "name": "Rare immune-related toxicities, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5304_8.5.1.0",
    "name": "RAS, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "RAS analysis [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.9.0",
    "name": "RAS mutant disease [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "RAS mutation status [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.1.0",
    "name": "RAS mutation [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.9.0",
    "name": "RAS wild-type disease [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Raynaud syndrome [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5094_4.2.0.0",
    "name": "RC [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5407_9.3.5.2",
    "name": "Reassessment after preop chemoradiotherapy, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.7.2.1",
    "name": "Reassessment after preoperative (chemo) radiotherapy [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5409_13.7.0.0",
    "name": "Rechallenge, summary [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5409_10.0.0.0",
    "name": "Rechallenge [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5281_5.0.0.0",
    "name": "RECIST criteria (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "RECIST [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5266_10.8.2.0",
    "name": "Recomm. to reduce cardiac toxicity in RT, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_9.2.0.0",
    "name": "Recommendations, reduce cardiac toxicity",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Recommendations, targeted therapy-associated stomatitis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Rectal cancer, diagnosis",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.6.3.0",
    "name": "Rectal cancer, histopathology",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.1.0.0",
    "name": "Rectal cancer, management of local/locoregional disease",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Rectal cancer, molecular biology",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_2.1.0.0",
    "name": "Rectal cancer, pathology",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.6.2.0",
    "name": "Rectal cancer, stage grouping",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.5.0.0",
    "name": "Rectal cancer, subclassification of T3 stage",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.4.0.0",
    "name": "Rectal cancer, TNM staging",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_2.2.0.0",
    "name": "Rectal cancer diagnosis interactive tool",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.1.0.0",
    "name": "Rectal cancer staging",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_3.2.0.0",
    "name": "Rectal cancer staging, interactive tool",
    "guidelineID": "47"
  },
  {
    "jumpto": "interactive_0001756",
    "name": "Rectal cancer surveillance and follow-up [tool]"
  },
  {
    "jumpto": "ENAS5407_4.1.0.0",
    "name": "Rectal cancer treatment, interactive tool",
    "guidelineID": "47"
  },
  {
    "jumpto": "interactive_0001749",
    "name": "Rectal cancer treatment of local recurrence [tool]"
  },
  {
    "jumpto": "interactive_0001747",
    "name": "Rectal cancer treatment recommendations [tool]"
  },
  {
    "jumpto": "interactive_0001751",
    "name": "Rectal cancer Tx of metastatic disease [tool]"
  },
  {
    "jumpto": "ENAS5071_5.0.0.0",
    "name": "Recurrence, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5407_4.4.0.0",
    "name": "Recurrence risk according to postop histology [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5265_5.4.0.0",
    "name": "Recurrent VTE, treatment",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.4.4.0",
    "name": "Recurrent VTE treatment, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Recursive partitioning analysis (RPA)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5266_9.2.0.0",
    "name": "Reduce cardiac toxicity, recommendations",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_9.2.0.0",
    "name": "Reduce cardiac toxicity by RT",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Reduced portal vein flow",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5268_2.7.0.0",
    "name": "Refractory emesis [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Refractory patients",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5281_3.2.0.0",
    "name": "Regional lymph nodes (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_5.14.5.0",
    "name": "Regorafenib [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5271_7.4.2.1",
    "name": "Relapsed and refractory DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5270_4.6.0.0",
    "name": "Relapsed cHL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.3.4.0",
    "name": "Relapsed cHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5273_5.6.0.0",
    "name": "Relapsed disease, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5274_4.5.0.0",
    "name": "Relapsed disease, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5273_8.3.3.0",
    "name": "Relapsed disease in FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5408_7.3.5.0",
    "name": "Relapsed disease in MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5274_7.3.3.0",
    "name": "Relapsed disease in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5408_4.6.0.0",
    "name": "Relapsed disease [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5270_5.3.0.0",
    "name": "Relapsed NLPHL, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.4.3.0",
    "name": "Relapsed NLPHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5279_4.2.3.2",
    "name": "Relapse treatment, interactive tool",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Remission induction chemotherapy [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Renal cell tumors, WHO classification",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5410_4.2.6.4",
    "name": "Renal toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.4.1",
    "name": "Renal toxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "Renal toxicity [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Resectable TETs, treatment algorithm [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Resistant patients with early relapse",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5269_5.10.2.0",
    "name": "Response assessment, algo. [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5064_5.0.0.0",
    "name": "Response assessment, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5407_4.7.2.1",
    "name": "Response assessment after preoperative (chemo) radiotherapy [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5281_5.0.0.0",
    "name": "Response evaluation (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5279_4.3.0.0",
    "name": "Response evaluation, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_4.6.1.0",
    "name": "Response evaluation, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_4.7.0.0",
    "name": "Response evaluation, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5273_5.8.0.0",
    "name": "Response evaluation, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_4.3.0.0",
    "name": "Response evaluation, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_5.4.0.0",
    "name": "Response evaluation, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_4.6.0.0",
    "name": "Response evaluation, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5281_7.4.0.0",
    "name": "Response evaluation, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_9.6.0.0",
    "name": "Response evaluation, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5274_4.6.0.0",
    "name": "Response evaluation, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5304_8.8.0.0",
    "name": "Response evaluation and follow-up, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5277_7.5.0.0",
    "name": "Response evaluation and follow-up in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5304_7.0.0.0",
    "name": "Response evaluation and follow-up [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5277_6.0.0.0",
    "name": "Response evaluation and follow up, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "Response evaluation criteria in solid tumours (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5098_5.10.0.0",
    "name": "Response evaluation criteria [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5271_7.3.4.0",
    "name": "Response evaluation in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.3.7.0",
    "name": "Response evaluation in DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5273_8.3.5.0",
    "name": "Response evaluation in FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.3.3.0",
    "name": "Response evaluation in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_9.4.4.0",
    "name": "Response evaluation in HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.3.3.0",
    "name": "Response evaluation in MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5408_7.3.6.0",
    "name": "Response evaluation in MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5274_7.3.4.0",
    "name": "Response evaluation in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5408_4.7.0.0",
    "name": "Response evaluation [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5285_8.0.0.0",
    "name": "Response evaluation [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5279_7.3.3.0",
    "name": "Response revaluation in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5062_8.5.0.0",
    "name": "Response to treatment evaluation in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Reverse transcription-polymerase chain reaction (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5276_3.3.0.0",
    "name": "Revised clinical staging system, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5410_4.2.6.3",
    "name": "Rheumatological toxicity, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.3.1",
    "name": "Rheumatological toxicity [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5407_9.3.1.1",
    "name": "Risk adapted treatment of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.3.1.0",
    "name": "Risk adapted treatment [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_9.3.1.1",
    "name": "Risk adapted Tx, summary [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "Risk assessment (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "Risk assessment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "Risk assessment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_3.1.0.0",
    "name": "Risk assessment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5279_3.1.0.0",
    "name": "Risk assessment, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_3.1.0.0",
    "name": "Risk assessment, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_3.1.0.0",
    "name": "Risk assessment, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.1.0.0",
    "name": "Risk assessment, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Risk assessment, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5273_4.1.0.0",
    "name": "Risk assessment, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5270_3.0.0.0",
    "name": "Risk assessment, hodgkin's lymphoma",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_3.0.0.0",
    "name": "Risk assessment, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5406_4.6.0.0",
    "name": "Risk assessment, pretreatment [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5277_3.0.0.0",
    "name": "Risk assessment, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5407_3.1.0.0",
    "name": "Risk assessment, rectal CA",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5284_7.2.0.0",
    "name": "Risk assessment, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5263_14.8.6.0",
    "name": "Risk assessment, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_9.3.0.0",
    "name": "Risk assessment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5274_3.1.0.0",
    "name": "Risk assessment, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5064_7.2.0.0",
    "name": "Risk assessment in HCC, summary",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5284_3.1.0.0",
    "name": "Risk assessment [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5408_3.1.0.0",
    "name": "Risk assessment [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5263_9.6.0.0",
    "name": "Risk assessment [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_5.2.1.1",
    "name": "Risk assessment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5268_6.2.2.0",
    "name": "Risk classification, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_3.3.0.0",
    "name": "Risk classification [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5262_5.2.0.0",
    "name": "Risk factors, catheter-induced thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Risk factors, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Risk factors, extravasation [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Risk factors, patient-related [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_4.0.0.0",
    "name": "Risk factors, procedure-related [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.3.0.0",
    "name": "Risk factors, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5265_2.1.0.0",
    "name": "Risk factors, VTE [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.1.0.0",
    "name": "Risk factors for VTE, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5262_6.4.2.0",
    "name": "Risk factors of catheter-induced thrombosis, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5061_8.1.0.0",
    "name": "Risk factors of early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5407_9.3.2.0",
    "name": "Risk of recurrence of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5280_3.0.0.0",
    "name": "Risk stratification, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5409_11.2.3.0",
    "name": "Rituximab [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5268_2.2.2.0",
    "name": "Rolapitant [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Role, bisphosphonates [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Role, radiotherapy [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Role, surgery and local therapy",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5279_4.2.4.0",
    "name": "Role of HSCT",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_7.3.2.4",
    "name": "Role of HSCT, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5285_9.4.2.3",
    "name": "Role of radiotherapy and bisphosphonates, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.4.2.1",
    "name": "Role of surgery and local therapy, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5268_6.1.3.1",
    "name": "Route of administration of antiemetics, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Route of application of G-CSF, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Route of application of pegfilgrastim, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "RT-PCR, diagnosis (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_2.2.0.0",
    "name": "RT-PCR, reverse transcription polymerase chain reaction (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.10.0.0",
    "name": "RT in stage IV NSCLC",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.9.0",
    "name": "RT in stage IV NSCLC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "RT [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5098_5.5.0.0",
    "name": "RT [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5262_4.3.7.0",
    "name": "S. lugdunensis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5268_6.1.3.1",
    "name": "Safety of antiemetics, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5282_6.0.0.0",
    "name": "Salvage surgery (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5062_4.9.0.0",
    "name": "Salvage surgical treatment, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5062_8.3.8.0",
    "name": "Salvage surgical treatment in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5097_7.3.4.0",
    "name": "Salvage treatment, summary [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.5.1.0",
    "name": "Salvage treatment, TS/ T-NS",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5281_7.3.2.2",
    "name": "SCC first-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.2",
    "name": "SCC second-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5268_6.1.3.1",
    "name": "Schedule of antiemetics, summary [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Schedule of G-CSF, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.3.2.0",
    "name": "Schedule of pegfilgrastim, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_3.1.3.2",
    "name": "Schematic of body surface area [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5071_6.5.0.0",
    "name": "SCLC follow-up, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Screening, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5061_8.1.0.0",
    "name": "Screening for early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5406_2.0.0.0",
    "name": "Screening [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "SCT [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5283_4.6.0.0",
    "name": "Second- and further-line treatment (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.4.0",
    "name": "Second- and further-line treatment, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5304_8.6.10.0",
    "name": "Second-line therapy, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.7.1.0",
    "name": "Second-line treatment (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.6.1",
    "name": "Second-line treatment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_9.4.2.2",
    "name": "Second-line treatment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5281_4.7.3.0",
    "name": "Second-line treatment of NSCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.7.2.0",
    "name": "Second-line treatment of SCC (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_6.2.2.5",
    "name": "Second-line treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Secondary chemoprevention [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5269_6.3.1.0",
    "name": "Secondary prophylaxis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_4.1.0.0",
    "name": "Secondary prophylaxis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Selective internal radiotherapy (SIRT) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5062_3.1.0.0",
    "name": "Sentinel lymph node biopsy",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5267_12.7.0.0",
    "name": "Severe tissue damage, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_8.0.0.0",
    "name": "Severe tissue damage, surgical mgmt. [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5086_5.4.1.0",
    "name": "Short course radiotherapy, MPM",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5283_8.5.0.0",
    "name": "Signet cell tumours, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5268_2.1.0.0",
    "name": "Single IV antineoplastics [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5092_4.3.2.0",
    "name": "Sipleucel-T [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.1.0.0",
    "name": "Sipuleucel-T [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5410_4.2.1.2",
    "name": "Skin toxicities diagnosis & pathology, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5281_4.1.0.0",
    "name": "Smoking cessation, management (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5071_5.0.0.0",
    "name": "Smoking cessation counselling, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Sodium thiosulfate [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "Solitary metastatic lesion (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5268_5.2.0.0",
    "name": "Somatostatin analogues [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5064_4.4.0.0",
    "name": "Sorafenib, in HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "Sorafenib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5271_7.3.3.0",
    "name": "Special considerations for some DLBCLs",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5269_5.9.1.0",
    "name": "Specific indications, overview [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.1",
    "name": "Specific indications, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5267_12.6.3.0",
    "name": "Specific measures, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_7.3.0.0",
    "name": "Specific measures [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5283_8.5.0.0",
    "name": "Specific situations, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5407_3.6.4.0",
    "name": "Specimen grading in mesorectal excision [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5062_4.8.0.0",
    "name": "Sperm banking",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Spinal cord compression, metastatic PC",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Spinal cord compression [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5280_4.5.0.0",
    "name": "Splenectomy, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_7.3.5.0",
    "name": "Splenectomy in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5282_2.0.0.0",
    "name": "Squamous cell carcinomas (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5282_4.1.5.0",
    "name": "Squamous cell carcinomas, management (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5285_5.2.1.2",
    "name": "SSIGN score [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5061_5.3.0.0",
    "name": "Stage 0 treatment, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5407_3.6.2.0",
    "name": "Stage grouping, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5270_5.1.0.0",
    "name": "Stage IA treatment of NLPHL, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.4.1.0",
    "name": "Stage IA treatment of NLPHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5061_5.3.0.0",
    "name": "Stage IIA treatment, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5061_5.3.0.0",
    "name": "Stage III treatment, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5406_4.8.0.0",
    "name": "Stage I lung CA with emphysema, interactive tool [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5061_5.3.0.0",
    "name": "Stage I treatment, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5283_3.1.0.0",
    "name": "Staging (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_3.1.0.0",
    "name": "Staging (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_3.1.0.0",
    "name": "Staging (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5068_3.0.0.0",
    "name": "Staging (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5279_3.1.0.0",
    "name": "Staging, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_3.1.0.0",
    "name": "Staging, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_3.1.0.0",
    "name": "Staging, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.1.0.0",
    "name": "Staging, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Staging, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5273_4.1.0.0",
    "name": "Staging, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_3.0.0.0",
    "name": "Staging, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Staging, hepatocellular cancer",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5270_3.0.0.0",
    "name": "Staging, hodgkin's lymphoma",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_3.0.0.0",
    "name": "Staging, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5276_3.1.0.0",
    "name": "Staging, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5277_3.0.0.0",
    "name": "Staging, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5407_3.1.0.0",
    "name": "Staging, rectal CA",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5071_3.1.0.0",
    "name": "Staging, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5284_7.2.0.0",
    "name": "Staging, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5263_14.8.1.0",
    "name": "Staging, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_9.3.0.0",
    "name": "Staging, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5274_3.1.0.0",
    "name": "Staging, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5406_4.1.0.0",
    "name": "Staging and risk assessment, NSCLC [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5278_3.9.0.0",
    "name": "Staging and risk assessment, PBL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.8.1.0",
    "name": "Staging and risk assessment, PCNSL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.6.0.0",
    "name": "Staging and risk assessment, PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_3.7.0.0",
    "name": "Staging and risk assessment, PTL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5283_8.2.0.0",
    "name": "Staging and risk assessment, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_7.2.0.0",
    "name": "Staging and risk assessment, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_7.2.0.0",
    "name": "Staging and risk assessment, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5098_8.2.0.0",
    "name": "Staging and risk assessment, summary [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5279_7.2.0.0",
    "name": "Staging and risk assessment of CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_7.2.0.0",
    "name": "Staging and risk assessment of DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.2.1.0",
    "name": "Staging and risk assessment of DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5273_8.2.0.0",
    "name": "Staging and risk assessment of FL, summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5270_9.2.0.0",
    "name": "Staging and risk assessment of HL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.2.0.0",
    "name": "Staging and risk assessment of MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5408_7.2.1.0",
    "name": "Staging and risk assessment of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5278_7.2.5.0",
    "name": "Staging and risk assessment of PBL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_7.2.6.0",
    "name": "Staging and risk assessment of PBoL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5092_7.2.0.0",
    "name": "Staging and risk assessment of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5278_7.2.4.0",
    "name": "Staging and risk assessment of PCNSL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_7.2.2.0",
    "name": "Staging and risk assessment of PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5277_7.2.0.0",
    "name": "Staging and risk assessment of PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5278_7.2.3.0",
    "name": "Staging and risk assessment of PTL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5407_9.2.1.0",
    "name": "Staging and risk assessment of rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5274_7.2.0.0",
    "name": "Staging and risk assessment of WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5280_7.2.0.0",
    "name": "Staging and risk stratification of HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5061_8.3.0.0",
    "name": "Staging of early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5064_3.1.0.0",
    "name": "Staging of HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5086_7.3.0.0",
    "name": "Staging of MPM, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5068_8.2.0.0",
    "name": "Staging of pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5276_7.2.0.0",
    "name": "Staging of PCLs, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5096_7.2.0.0",
    "name": "Staging of PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5071_6.2.0.0",
    "name": "Staging of SCLC, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5279_3.2.0.0",
    "name": "Staging systems for CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5098_4.1.0.0",
    "name": "Staging TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5284_3.1.0.0",
    "name": "Staging [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5408_3.1.0.0",
    "name": "Staging [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5263_9.1.0.0",
    "name": "Staging [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5061_3.0.0.0",
    "name": "Standard pathological assessment",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5304_5.11.0.0",
    "name": "Standard treatment algorithm, oligometastatic disease [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5262_6.3.3.6",
    "name": "Staphylococcus aureus, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.8.0",
    "name": "Staphylococcus aureus [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_6.3.3.5",
    "name": "Staphylococcus coagulase-negative, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.7.0",
    "name": "Staphylococcus coagulase-negative [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5285_2.0.0.0",
    "name": "Stauf­fer’s syn­drome [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Steatorrhoea (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5277_4.8.0.0",
    "name": "Stem cell transplantation, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5277_7.3.6.0",
    "name": "Stem cell transplantation in PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "Stem cell transplantation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Stent, advanced pancreatic cancer",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5267_9.2.0.0",
    "name": "Steps, CVAD extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_7.4.0.0",
    "name": "Steps, peripheral line extravasation",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Stereotactic ablative body radiotherapy (SBRT) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5406_5.1.3.0",
    "name": "Stereotactic body radiotherapy [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Stereotactic radiosurgery (SRS)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Steroids [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5410_3.1.2.0",
    "name": "Stevens John­son syndrome [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5263_14.1.0.0",
    "name": "Stomatitis, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.5.0.0",
    "name": "Stomatitis in targeted therapy, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_6.0.0.0",
    "name": "Stomatitis in targeted therapy [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_2.0.0.0",
    "name": "Stomatitis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Stool DNA testing",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Sub-total gastrectomy, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5276_4.5.0.0",
    "name": "Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.6.0",
    "name": "Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5061_5.2.0.0",
    "name": "Subtotal colectomy",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Succinate dehydrogenase-deficient RCCs",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Sucralfate enemas [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Sucralfate mouthwash [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.3.0",
    "name": "Sulfasalazine [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5283_8.1.0.0",
    "name": "Summary of recommendations (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_7.1.0.0",
    "name": "Summary of recommendations (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_7.1.0.0",
    "name": "Summary of recommendations (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5062_8.1.0.0",
    "name": "Summary of recommendations, anal cancer",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5284_7.1.0.0",
    "name": "Summary of recommendations, biliary cancer",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5279_7.1.0.0",
    "name": "Summary of recommendations, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5262_6.1.0.0",
    "name": "Summary of recommendations, CVC",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5266_10.1.0.0",
    "name": "Summary of recommendations, CV Tox",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5271_7.1.0.0",
    "name": "Summary of recommendations, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.1.1.0",
    "name": "Summary of recommendations, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5061_8.1.0.0",
    "name": "Summary of recommendations, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5267_12.1.0.0",
    "name": "Summary of recommendations, Extra",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5273_8.1.0.0",
    "name": "Summary of recommendations, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5269_6.1.0.0",
    "name": "Summary of recommendations, FN",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5064_7.1.0.0",
    "name": "Summary of recommendations, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5280_7.1.0.0",
    "name": "Summary of recommendations, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5270_9.1.0.0",
    "name": "Summary of recommendations, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5275_7.1.0.0",
    "name": "Summary of recommendations, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5263_14.1.0.0",
    "name": "Summary of recommendations, Mucosa",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5268_6.1.1.0",
    "name": "Summary of recommendations, N/V",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5276_7.1.0.0",
    "name": "Summary of recommendations, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5277_7.1.0.0",
    "name": "Summary of recommendations, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5285_9.1.0.0",
    "name": "Summary of recommendations, RCC",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5071_6.1.0.0",
    "name": "Summary of recommendations, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_8.1.0.0",
    "name": "Summary of recommendations, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5265_8.1.0.0",
    "name": "Summary of recommendations, VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5274_7.1.0.0",
    "name": "Summary of recommendations, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5408_7.1.0.0",
    "name": "Summary of recommendations [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_8.1.0.0",
    "name": "Summary of recommendations [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.2.2.3",
    "name": "Sunitinib [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5068_4.1.0.0",
    "name": "Superior mesenteric artery (SMA)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Supernumerary teeth",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5068_5.7.1.0",
    "name": "Supportive care (Pancreatic Cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5062_8.3.7.0",
    "name": "Supportive care in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5280_4.8.0.0",
    "name": "Supportive treatment, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_7.3.8.0",
    "name": "Supportive treatment of HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Surgery, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Surgery, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Surgery and local therapy, role",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5062_8.3.2.0",
    "name": "Surgery in anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5086_7.4.4.0",
    "name": "Surgery in MPM, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5304_5.2.1.0",
    "name": "Surgery [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.4.0.0",
    "name": "Surgical criteria [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5267_12.7.0.0",
    "name": "Surgical debridement, summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_8.0.0.0",
    "name": "Surgical debridement [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_8.0.0.0",
    "name": "Surgical mgmt., severe tissue damage [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_12.7.0.0",
    "name": "Surgical mgmt., summary [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5265_4.1.0.0",
    "name": "Surgical patients, prevention of VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5283_4.3.1.0",
    "name": "Surgical resection, management (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5304_8.6.2.2",
    "name": "Surgical resection, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Surgical resection [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5304_5.2.2.0",
    "name": "Surgical resection [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Surgical staging, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5406_5.1.1.0",
    "name": "Surgical treatment, stage I and II [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5098_5.4.0.0",
    "name": "Surgical treatment, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5096_7.3.1.0",
    "name": "Surgical treatment of PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_8.3.2.0",
    "name": "Surgical treatment of TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5407_8.2.0.0",
    "name": "Surveillance and follow-up, tool [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5096_6.3.0.0",
    "name": "Surveillance [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5098_4.2.0.0",
    "name": "Survival rates, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5285_9.6.0.0",
    "name": "Survivorship, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5061_7.0.0.0",
    "name": "Survivorship care",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5285_8.0.0.0",
    "name": "Survivorship [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5269_6.4.6.6",
    "name": "Suspected meningitis, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.6.0",
    "name": "Suspected meningitis [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_6.4.6.5",
    "name": "Suspected viral infection, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.5.0",
    "name": "Suspected viral infection [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_3.1.2.0",
    "name": "Sweet syndrome [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5266_3.4.2.0",
    "name": "Symptomatic LVD [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Symptoms (Pancreatic Cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5263_11.1.0.0",
    "name": "Systematic enteral nutrition, emergent data [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.3.0.0",
    "name": "Systematic enteral nutrition, emergent data [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5098_5.4.0.0",
    "name": "Systematic lymphadenectomy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5284_7.3.2.2",
    "name": "Systemic chemotherapy, summary [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5284_4.4.2.0",
    "name": "Systemic chemotherapy [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5304_5.7.0.0",
    "name": "Systemic perioperative therapy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5281_4.1.0.0",
    "name": "Systemic therapy, management (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_5.14.8.0",
    "name": "Systemic therapy choices [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.2.2.2",
    "name": "Systemic treatment, algorithm [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.2.1",
    "name": "Systemic treatment, overview [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.4.2.2",
    "name": "Systemic treatment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5276_4.3.0.0",
    "name": "Sézary syndrome (SS)",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5276_7.3.4.0",
    "name": "Sézary syndrome (SS), summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5097_4.4.2.0",
    "name": "T-NS, standard treatment strategies",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, for high-risk stage I",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, for low-risk stage I",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, for stage IIA/IIB marker-negative disease",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, for stage IIA/IIB marker-positive disease",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, for stage IS/ II/III",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.4.1.0",
    "name": "T-NS treatment, overview",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_7.3.2.0",
    "name": "T-NS treatment, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5285_9.4.1.1",
    "name": "T1 tumours (&lt;7 cm), summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "T1 tumours (&lt;7 cm) [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_9.4.1.2",
    "name": "T2 tumours (&gt;7 cm), summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.1.2.0",
    "name": "T2 tumours (&gt;7 cm) [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "TACE",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Targeted therapy-associated stomatitis, recommendations [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.8.5.0",
    "name": "Targeted therapy-associated stomatitis grading, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_9.5.0.0",
    "name": "Targeted therapy-associated stomatitis grading [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Taurolidine [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5062_4.11.0.0",
    "name": "Taxanes [Anal cancr]",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Taxanes [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5409_11.1.4.0",
    "name": "Taxanes [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "TBI [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5263_5.0.0.0",
    "name": "Tegafur [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5285_6.2.2.4",
    "name": "Temsirolimus [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5263_14.1.0.0",
    "name": "Terminology, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_2.0.0.0",
    "name": "Terminology [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "Testicular germ cell tumour (TGCT) [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5098_5.12.0.0",
    "name": "TET chemotherapy agents",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_8.5.0.0",
    "name": "TETs follow-up, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "TGF-α [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5280_4.10.0.0",
    "name": "Therapeutic algo. for HCL-V, interactive tool",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5273_5.3.2.0",
    "name": "Therapeutic algorithm, interactive tool",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5098_5.2.0.0",
    "name": "Therapeutic strategies, thymic carcinoma [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_5.2.0.0",
    "name": "Therapeutic strategies, thymoma [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5304_8.6.8.0",
    "name": "Therapeutic strategy, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Therapeutic strategy [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.11.0",
    "name": "Third-line therapy, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_9.4.2.2",
    "name": "Third-line treatment, summary [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.2.6",
    "name": "Third-line treatment [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5265_5.1.2.0",
    "name": "Thrombolytic therapy, acute treatment [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5098_5.4.0.0",
    "name": "Thymectomy [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Thymic carcinomas [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Thymic epithelial tumours (TETs)",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Thymidylate synthase (TS) activity [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5098_2.0.0.0",
    "name": "Thymomas [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "interactive_0001763",
    "name": "Thyroid function, interactive tool [irAEs]"
  },
  {
    "jumpto": "ENAS5410_3.2.1.2",
    "name": "Thyroid function monitoring, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.2.1.3",
    "name": "Thyroid function – TSH, interactive tool [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_4.2.2.1",
    "name": "Thyroid gland disorders, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.2.1.1",
    "name": "Thyroid gland disorders [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Tinzaparin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5304_8.3.0.0",
    "name": "Tissue handling, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.4.0.0",
    "name": "Tissue selection for biomarker testing, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5276_3.2.0.0",
    "name": "TNMB classification, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5407_3.6.2.0",
    "name": "TNM pathological classification [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5283_3.2.0.0",
    "name": "TNM staging (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5281_3.2.0.0",
    "name": "TNM staging (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5282_3.2.0.0",
    "name": "TNM staging (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5061_4.2.0.0",
    "name": "TNM staging, early colon cancer",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5407_3.4.0.0",
    "name": "TNM staging, rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5071_3.2.0.0",
    "name": "TNM staging, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_4.3.0.0",
    "name": "TNM staging, TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5406_4.4.0.0",
    "name": "TNM staging [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5285_5.1.0.0",
    "name": "TNM staging [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Toolbox of ablative treatments [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.5.0",
    "name": "Toolbox of LATs, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.12.0.0",
    "name": "Toolbox of LATs [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5267_7.5.0.0",
    "name": "Topical DMSO [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5263_11.4.0.0",
    "name": "Topical [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Topoisomerase II inhibitors [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Topoisomerase I inhibitors [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Topotecan, second-line treatment [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5268_2.9.0.0",
    "name": "Total body irradiation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5268_3.3.0.0",
    "name": "Total nodal irradiation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Total testosterone [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5304_8.5.4.0",
    "name": "Toxicity biomarkers, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Toxicity biomarkers [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5282_7.2.0.0",
    "name": "Tracheo-bronchoscopy, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5262_4.3.8.0",
    "name": "Trans-oesophageal echocardiogram [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5304_5.3.0.0",
    "name": "Transarterial chemoembolisation (TACE) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5064_4.3.0.0",
    "name": "Transcatheter devices, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Transdermal fentanyl [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5304_4.2.5.0",
    "name": "Transforming growth factor-α [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5282_4.1.3.0",
    "name": "Transthoracic oesophagectomy, surgical technique (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5094_2.0.0.0",
    "name": "Transurethral resection of the bladder tumour (TURBT)",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5266_3.4.2.0",
    "name": "Trastuzumab cardiotoxicity, mgmt.",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_3.4.1.0",
    "name": "Trastuzumab cardiotoxicity, overview",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5409_11.2.4.0",
    "name": "Trastuzumab [IRs]",
    "guidelineID": "49"
  },
  {
    "jumpto": "ENAS5282_4.1.2.0",
    "name": "Treat. of local/ locoregional Oes CA, interactive tool",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5283_4.1.0.0",
    "name": "Treatment (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_4.1.1.0",
    "name": "Treatment (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5262_5.4.0.0",
    "name": "Treatment, catheter-induced thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_5.5.1.0",
    "name": "Treatment, catheter-related thrombosis [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5279_4.1.0.0",
    "name": "Treatment, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5271_4.4.0.0",
    "name": "Treatment, CNS prophylaxis (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5262_4.3.1.0",
    "name": "Treatment, CVC infections",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5271_4.1.0.0",
    "name": "Treatment, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_4.1.0.0",
    "name": "Treatment, DLBCL-PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5407_4.3.2.0",
    "name": "Treatment, early rectal cancer not suitable for local excision",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5304_5.14.10.4",
    "name": "Treatment, elderly patients [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.10.2",
    "name": "Treatment, fit patients with symptomatic disease [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Treatment, fit patients [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5273_5.1.1.0",
    "name": "Treatment, FL",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_4.1.0.0",
    "name": "Treatment, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5407_4.3.3.0",
    "name": "Treatment, intermediate/more locally advanced rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5284_4.1.0.0",
    "name": "Treatment, introduction [Bil]",
    "guidelineID": "43"
  },
  {
    "jumpto": "ENAS5061_5.2.0.0",
    "name": "Treatment, localised disease [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5071_4.2.0.0",
    "name": "Treatment, localised disease [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5406_5.2.1.0",
    "name": "Treatment, locally advanced (stage III) NSCLC [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5407_4.3.4.0",
    "name": "Treatment, locally advanced rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5061_5.1.0.0",
    "name": "Treatment, malignant polyps",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5275_4.1.0.0",
    "name": "Treatment, MALT",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5285_6.2.1.0",
    "name": "Treatment, management of metastatic disease [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "Treatment, metastatic disease [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5285_6.1.1.0",
    "name": "Treatment, mgmt. of local/ locoregional disease [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5285_6.2.2.7",
    "name": "Treatment, non-clear cell histology [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5406_5.1.1.0",
    "name": "Treatment, NSCLC stages I and II [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5278_4.5.0.0",
    "name": "Treatment, PBL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_4.6.0.0",
    "name": "Treatment, PBoL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5276_4.1.0.0",
    "name": "Treatment, PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5278_4.4.0.0",
    "name": "Treatment, PCNSL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_4.2.0.0",
    "name": "Treatment, PMBCL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5277_4.1.0.0",
    "name": "Treatment, PTCL",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5278_4.3.0.0",
    "name": "Treatment, PTL",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5407_4.2.0.0",
    "name": "Treatment, rectal cancer without distant mets. [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_4.3.5.0",
    "name": "Treatment, rectal tumours with threatened resection margin [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5265_5.4.0.0",
    "name": "Treatment, recurrent VTE",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5271_5.2.2.0",
    "name": "Treatment, response evaluation and FU (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_7.4.2.2",
    "name": "Treatment, response evaluation and FU in DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_4.5.0.0",
    "name": "Treatment, special considerations for some DLBCLs",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5406_5.1.1.0",
    "name": "Treatment, stage II [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5406_5.1.1.0",
    "name": "Treatment, stage I [Early NSCLC]",
    "guidelineID": "46"
  },
  {
    "jumpto": "ENAS5283_8.3.1.1",
    "name": "Treatment, summary (Gastric cancer)",
    "guidelineID": "42"
  },
  {
    "jumpto": "ENAS5282_7.3.1.1",
    "name": "Treatment, summary (Oes CA)",
    "guidelineID": "41"
  },
  {
    "jumpto": "ENAS5304_8.6.1.0",
    "name": "Treatment, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.10.3",
    "name": "Treatment, unfit patients [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Treatment, unfit patients [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5407_4.3.1.0",
    "name": "Treatment, very early rectal cancer",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5274_4.1.0.0",
    "name": "Treatment, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5274_4.3.0.0",
    "name": "Treatment algo. for WM: Newly diagnose, interactive tool",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5274_4.4.0.0",
    "name": "Treatment algo. for WM: Relapse, interactive tool",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5071_4.1.0.0",
    "name": "Treatment algorithm, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Treatment algorithms [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5262_6.3.3.4",
    "name": "Treatment duration, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5262_4.3.6.0",
    "name": "Treatment duration [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5280_4.7.0.0",
    "name": "Treatment during pregnancy, HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5063_4.5.0.0",
    "name": "Treatment follow-up [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5281_4.9.2.0",
    "name": "Treatment for stage IIIB-IV with ALK translocation, interactive tool",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.8.2.0",
    "name": "Treatment for stage IIIB–IV with EGFR mutation, interactive tool",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.2.2.0",
    "name": "Treatment for stage IV NSCC, interactive tool",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.2.1.0",
    "name": "Treatment for stage IV SCC, interactive tool",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_8.3.5.0",
    "name": "Treatment in elderly with anal cancer, summary",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5279_4.2.1.0",
    "name": "Treatment of advanced-stage disease, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_7.3.2.1",
    "name": "Treatment of advanced-stage disease in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5098_5.7.0.0",
    "name": "Treatment of advanced TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_4.1.0.0",
    "name": "Treatment of asymptomatic patients, WM",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5274_7.3.1.0",
    "name": "Treatment of asymptomatic patients in WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5262_6.4.4.0",
    "name": "Treatment of catheter-induced thrombosis, summary [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5270_4.1.0.0",
    "name": "Treatment of cHL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_4.5.0.0",
    "name": "Treatment of cHL, advanced-stage",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_4.4.0.0",
    "name": "Treatment of cHL, intermediate-stage",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_4.3.0.0",
    "name": "Treatment of cHL, limited-stage",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.3.1.0",
    "name": "Treatment of cHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5279_4.2.5.0",
    "name": "Treatment of CLL, complications",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_4.2.2.1",
    "name": "Treatment of CLL, front-line",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_7.3.1.0",
    "name": "Treatment of CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_7.3.2.5",
    "name": "Treatment of CLL complications, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5092_7.3.2.2",
    "name": "Treatment of CRPC, summary [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5262_6.3.3.1",
    "name": "Treatment of CVC infections, summary",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5271_7.3.1.0",
    "name": "Treatment of DLBCL, summary",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5278_7.3.1.0",
    "name": "Treatment of DLBCL-PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5279_7.3.1.0",
    "name": "Treatment of early-stage disease in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5407_9.3.1.2",
    "name": "Treatment of early rectal cancer not suitable for local excision, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5279_4.1.0.0",
    "name": "Treatment of early stage disease, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5408_7.3.3.0",
    "name": "Treatment of elderly patients of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_4.4.0.0",
    "name": "Treatment of elderly patients [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5273_8.3.1.0",
    "name": "Treatment of FL, Summary",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5280_7.3.1.0",
    "name": "Treatment of HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_4.9.0.0",
    "name": "Treatment of HCL-V",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_7.3.9.0",
    "name": "Treatment of HCL-V, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5407_9.3.1.3",
    "name": "Treatment of intermediate rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5061_8.4.2.0",
    "name": "Treatment of localised early colon cancer, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5071_6.3.1.0",
    "name": "Treatment of localised SCLC, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5407_9.3.1.4",
    "name": "Treatment of locally advanced rectal cancer, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5407_5.2.0.0",
    "name": "Treatment of local recurrence of rectal cancer, tool [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5061_8.4.1.0",
    "name": "Treatment of malignant polyps, summary",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5275_7.3.1.0",
    "name": "Treatment of MALT, summary",
    "guidelineID": "34"
  },
  {
    "jumpto": "ENAS5408_7.3.1.0",
    "name": "Treatment of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_8.6.7.0",
    "name": "Treatment of metastatic disease, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5407_6.2.0.0",
    "name": "Treatment of metastatic disease, tool [Rectal CA]",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5068_8.3.6.0",
    "name": "Treatment of metastatic pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5071_6.3.2.0",
    "name": "Treatment of metastatic SCLC, summary",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Treatment of metastatic TETs, interactive tool",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5094_9.3.2.0",
    "name": "Treatment of MIBC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5086_7.4.1.0",
    "name": "Treatment of MPM, summary",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5270_5.1.0.0",
    "name": "Treatment of NLPHL, HL",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5270_9.4.1.0",
    "name": "Treatment of NLPHL, summary",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5094_9.3.1.0",
    "name": "Treatment of NMIBC, summary",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5068_8.3.5.0",
    "name": "Treatment of non-resectable pancreatic cancer, summary",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5281_4.15.0.0",
    "name": "Treatment of oligometastatic NSCLC",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_7.3.14.0",
    "name": "Treatment of oligometastatic NSCLC, summary (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5278_7.3.5.0",
    "name": "Treatment of PBL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5278_7.3.6.0",
    "name": "Treatment of PBoL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5276_7.3.1.0",
    "name": "Treatment of PCLs, summary",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5278_7.3.4.0",
    "name": "Treatment of PCNSL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5096_7.3.1.0",
    "name": "Treatment of PenCa, summary",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5278_7.3.2.0",
    "name": "Treatment of PMBCL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5277_7.3.1.0",
    "name": "Treatment of PTCL, summary",
    "guidelineID": "36"
  },
  {
    "jumpto": "ENAS5278_7.3.3.0",
    "name": "Treatment of PTL, summary",
    "guidelineID": "37"
  },
  {
    "jumpto": "ENAS5098_5.11.0.0",
    "name": "Treatment of recurrences in TETs",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_8.3.9.0",
    "name": "Treatment of recurrences in TETs, summary",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5265_8.4.4.0",
    "name": "Treatment of recurrent VTE, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5092_7.3.1.4",
    "name": "Treatment of relapse of PC, summary",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Treatment of resectable TETs, interactive tool",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Treatment of unresectable TETs. Interactive tool",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5274_7.3.1.0",
    "name": "Treatment of WM, summary",
    "guidelineID": "33"
  },
  {
    "jumpto": "ENAS5408_7.3.4.0",
    "name": "Treatment of younger patients of MCL, summary",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5408_4.5.0.0",
    "name": "Treatment of younger patients [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5271_4.2.5.0",
    "name": "Treatment strategies, >2 relapses/ progressions (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_4.2.1.0",
    "name": "Treatment strategies, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_4.2.3.0",
    "name": "Treatment strategies, elderly >60 years (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_4.2.4.0",
    "name": "Treatment strategies, first relapse/ progression (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5271_4.2.2.0",
    "name": "Treatment strategies, patients ≤60 years (DLBCL)",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Treatment stratification [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5271_4.3.0.0",
    "name": "Treatment stratified according to age, DLBCL",
    "guidelineID": "30"
  },
  {
    "jumpto": "ENAS5063_4.4.0.0",
    "name": "Treatment [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5408_4.1.0.0",
    "name": "Treatment [MCL]",
    "guidelineID": "48"
  },
  {
    "jumpto": "ENAS5304_5.1.0.0",
    "name": "Treatment [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.1.0.0",
    "name": "Treatment [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.5.0",
    "name": "Trifluridine/tipiracil [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5268_2.3.2.0",
    "name": "Tropisetron [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5092_2.0.0.0",
    "name": "TRUS guided prostate biopsy [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "TS/T-NS, diagnosis",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_6.0.0.0",
    "name": "TS/T-NS, follow-up and surveillance",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "TS/T-NS, iso-chromosome 12p",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_5.0.0.0",
    "name": "TS/T-NS, personalised medicine",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "TS/T-NS, post-orchiectomy staging",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.2.0",
    "name": "TS/T-NS, standard treatment strategies",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "TS/T-NS, syncytiotrophoblasts",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "TS/T-NS, TNM staging",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "TS/T-NS, WHO classification",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_7.1.0.0",
    "name": "TS/T-NS diagnosis, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "TS/T-NS staging",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "TS/T-NS staging, for metastatic disease",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "TS/T-NS staging, for stage I disease",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "TS/T-NS staging, IGCCCG prognostic groups",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_3.2.0.0",
    "name": "TS/T-NS staging, serum tumour markers",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_7.2.0.0",
    "name": "TS/T-NS staging, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.1.0.0",
    "name": "TS/T-NS treatment",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.1.0.0",
    "name": "TS/T-NS treatment, chemotherapy regimens",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "TS/T-NS treatment, for stage I",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "TS/T-NS treatment, for stage IIA",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "TS/T-NS treatment, for stage IIB/ IIC",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "TS/T-NS treatment, for stage III",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.3.1.0",
    "name": "TS/T-NS treatment, overview",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.2.0.0",
    "name": "TS/T-NS treatment chemotherapy regimens, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.6.0.0",
    "name": "TS/T-NS treatment in late relapse",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_4.7.0.0",
    "name": "TS/T-NS treatment in late toxicity",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "TS enhancer region (TSER) genotyping [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_7.3.1.0",
    "name": "TS treatment, summary",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5068_3.0.0.0",
    "name": "Tumor marker (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5064_4.1.0.0",
    "name": "Tumor recurrence, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5071_3.3.0.0",
    "name": "Tumor stage grouping, SCLC",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "Tumour biology [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5273_7.3.0.0",
    "name": "Tumour burden: Low/high, interactive tool",
    "guidelineID": "32"
  },
  {
    "jumpto": "ENAS5304_5.14.1.0",
    "name": "Tumour burden [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Tumour marker measurements [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_3.1.0.0",
    "name": "Tumour markers in staging [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "Tumour markers [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5281_2.1.0.0",
    "name": "Tumour rebiopsy at disease progression (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5062_4.4.1.0",
    "name": "Tumour shrinkage",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5407_9.3.1.5",
    "name": "Tumours with threatened resection margin, summary",
    "guidelineID": "47"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "TURBT [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5063_4.1.0.0",
    "name": "Turcot's syndrome [Fam. colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5061_2.0.0.0",
    "name": "Turcot syndrome",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5063_2.1.0.0",
    "name": "Turcot syndrome [Fam. Colorectal cancer]",
    "guidelineID": "12"
  },
  {
    "jumpto": "ENAS5266_9.3.0.0",
    "name": "Tx, radiotherapy-related cardiac complications [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5270_4.2.0.0",
    "name": "Tx algo. for cHL, interactive tool",
    "guidelineID": "29"
  },
  {
    "jumpto": "ENAS5280_7.3.7.0",
    "name": "Tx during pregnancy in HCL, summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5266_8.0.0.0",
    "name": "Tx of LVD, anticancer treatment [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5266_10.7.0.0",
    "name": "Tx of LVD induced by anticancer treatment, summary [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5279_4.2.3.1",
    "name": "Tx of relapsed and refractory disease, CLL",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5279_7.3.2.3",
    "name": "Tx of relapsed and refractory disease in CLL, summary",
    "guidelineID": "38"
  },
  {
    "jumpto": "ENAS5280_4.4.1.0",
    "name": "Tx of replapse & refra. pts., HCL",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5280_7.3.4.0",
    "name": "Tx of replapse & refra. pts., summary",
    "guidelineID": "39"
  },
  {
    "jumpto": "ENAS5410_4.2.2.3",
    "name": "Type 1 diabetes mellitus, summary [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5068_5.7.2.0",
    "name": "Tyrosine kinase inhibitor (TKI)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5285_5.2.1.3",
    "name": "UISS risk groups [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5094_3.1.0.0",
    "name": "Ultrasonography [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Ultrasonography [Early colon cancer]",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5096_6.3.0.0",
    "name": "Ultrasound-guided FNAC biopsy [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5266_2.0.0.0",
    "name": "Ultrasound assessment [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5304_8.6.12.2",
    "name": "Unfit patients, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.2.5",
    "name": "Unresectable colorectal liver metastases, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.8.0.0",
    "name": "Unresectable colorectal liver metastase [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5086_5.3.0.0",
    "name": "Unresectable mesothelioma, treatment recommendations",
    "guidelineID": "4"
  },
  {
    "jumpto": "ENAS5098_5.1.0.0",
    "name": "Unresectable TETs, treatment algorithm [TETs]",
    "guidelineID": "15"
  },
  {
    "jumpto": "ENAS5268_3.3.0.0",
    "name": "Upper body irradiation [N/V]",
    "guidelineID": "27"
  },
  {
    "jumpto": "ENAS5094_8.0.0.0",
    "name": "Urethral wash cytology [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5304_4.2.4.0",
    "name": "Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.12.1",
    "name": "Use of biologicals, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.6.0",
    "name": "Use of biologicals [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_8.6.12.1",
    "name": "Use of cytotoxics, summary [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_5.14.6.0",
    "name": "Use of cytotoxics [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5266_9.4.0.0",
    "name": "Valvular disease [CV Tox]",
    "guidelineID": "25"
  },
  {
    "jumpto": "ENAS5262_4.3.3.0",
    "name": "Vancomycin [CVC]",
    "guidelineID": "21"
  },
  {
    "jumpto": "ENAS5269_5.9.7.0",
    "name": "Vancomycin [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5410_3.6.5.0",
    "name": "Vascular endothelial growth factor",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5304_5.14.2.0",
    "name": "Vascular endothelial growth factor (VEGF) [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5265_8.4.5.0",
    "name": "Vena cava filter, summary [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.5.0.0",
    "name": "Vena cava filter [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5096_3.1.0.0",
    "name": "Verrucous carcinoma [PenCa]",
    "guidelineID": "19"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Vesicant [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5269_6.4.6.5",
    "name": "Vesicular lesions, summary [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5269_5.9.5.0",
    "name": "Vesicular lesions [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5064_5.0.0.0",
    "name": "Viable tumor assessment, HCC",
    "guidelineID": "7"
  },
  {
    "jumpto": "ENAS5267_3.0.0.0",
    "name": "Vinca alkaloids [Extra]",
    "guidelineID": "26"
  },
  {
    "jumpto": "ENAS5071_4.3.2.0",
    "name": "Vincristine, second-line treatment [SCLC]",
    "guidelineID": "3"
  },
  {
    "jumpto": "ENAS5094_5.2.0.0",
    "name": "Vinflunine, second line treatment [BC]",
    "guidelineID": "17"
  },
  {
    "jumpto": "ENAS5061_3.0.0.0",
    "name": "Virtual colonoscopy",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5061_4.1.0.0",
    "name": "Visceromegaly",
    "guidelineID": "10"
  },
  {
    "jumpto": "ENAS5410_3.6.5.0",
    "name": "Vogt-Koyanagi-Harada syndrome [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5410_3.6.5.0",
    "name": "Vogt-‍Koyanagi-‍Harada syn­drome [irAEs]",
    "guidelineID": "50"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "Von Hippel-Lindau gene alterations [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5269_5.9.4.0",
    "name": "Voriconazole [FN]",
    "guidelineID": "28"
  },
  {
    "jumpto": "ENAS5265_2.1.0.0",
    "name": "VTE, risk factors [VTE]",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_8.1.0.0",
    "name": "VTE risk factors, summary",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.1.1.0",
    "name": "VTE treatment, acute",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5265_5.2.0.0",
    "name": "VTE treatment, long-term",
    "guidelineID": "24"
  },
  {
    "jumpto": "ENAS5062_2.2.0.0",
    "name": "Vulval intra-epithelial neoplasis (VIN)",
    "guidelineID": "14"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Weight loss (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5285_3.0.0.0",
    "name": "WHO classification, renal cell tumors",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5276_2.0.0.0",
    "name": "WHO EORTC classification of PCLs",
    "guidelineID": "35"
  },
  {
    "jumpto": "ENAS5281_4.14.1.0",
    "name": "Whole brain radiotherapy (WBRT)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Whole exome analyses [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Whole genome analyses [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5068_2.0.0.0",
    "name": "Whole genome sequencing (Pancreatic cancer)",
    "guidelineID": "8"
  },
  {
    "jumpto": "ENAS5304_4.2.6.0",
    "name": "Whole transcriptome analyses [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5263_9.2.0.0",
    "name": "WHO scale, oral mucositis [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_14.8.2.0",
    "name": "WHO scale, summary [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5263_11.2.2.0",
    "name": "Zinc supplements [Mucosa]",
    "guidelineID": "22"
  },
  {
    "jumpto": "ENAS5092_4.4.0.0",
    "name": "Zoledronate [PC]",
    "guidelineID": "16"
  },
  {
    "jumpto": "ENAS5281_4.14.2.0",
    "name": "Zoledronic acid (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5281_4.14.2.0",
    "name": "Zoledronic acid reduces skeletal-related events (Metastatic NSCLC)",
    "guidelineID": "40"
  },
  {
    "jumpto": "ENAS5285_6.2.2.8",
    "name": "Zoledronic acid [RCC]",
    "guidelineID": "44"
  },
  {
    "jumpto": "ENAS5304_5.14.7.0",
    "name": "Zurich treatment algorithm [mCRC]",
    "guidelineID": "45"
  },
  {
    "jumpto": "ENAS5097_2.0.0.0",
    "name": "α-fetoprotein [TS/T-NS]",
    "guidelineID": "20"
  },
  {
    "jumpto": "ENAS5283_4.3.3.1",
    "name": "≥ stage IB gastric cancer",
    "guidelineID": "42"
  }
]